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RNA interference (RNAi), mediated by small interfering RNA (siRNA), has emerged as a 
powerful tool for elucidating gene function and also holds great potential for the treatment of 
acquired and inherited diseases. The delivery of siRNAs still remains a major obstacle for their 
therapeutic use. Cationic liposomes, a group of positively charged nanovesicles, represent a class 
of non-viral vectors that have shown the ability to efficiently bind and deliver siRNA.  
 
In this study, six cationic liposome formulations containing either cationic cholesterol derivative  
[N-(N’,N’-dimethylaminopropane)-carbamoyl] cholesterol (Chol-T) or N,N-
dimethylaminopropylaminylsuccinylcholesterylformyl- hydrazide (MSO9) were prepared with 
the neutral lipid dioleoylphosphatidylethanolamine (DOPE). Varying amounts of 
distearoylphosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG2000), (0, 2 and 5 mole 
percent) were also included in the liposomal formulations as polyethylene glycol is known to 
improve the lipoplex bioavailability in vivo.  
 
We present evidence that siRNA may be delivered to mammalian cells, in vitro, using a novel 
cationic liposome carrier system and that siRNA binding and transfection efficiency of the 
cationic liposomes are affected by the degree of pegylation. 
 
Cryoelectron microscopy revealed that the liposome vesicles were unilamellar and were in the  
30 - 130 nm size range, while band shift assays confirmed the formation of complexes between 
the siRNA and the liposome preparations. These siRNA lipoplexes were shown to afford 
protection to their siRNA cargoes against serum nuclease degradation and were also shown to 
be relatively non-toxic to the HeLa tat luc cell line which stably expresses the firefly luciferase 
gene. Cryoelectron microscopy revealed that an inverse relationship exists between the lipoplex 
size and the degree of pegylation. To determine the transfection efficiency of the cationic 
liposome preparations in the HeLa tat luc cell line, complexes were prepared with anti-luciferase 
siRNA, which is specific for the firefly luciferase gene, and knockdown of the luciferase gene 
was monitored in transfected cells. The results show that liposomes containing the cytofectin 
iii 
 
Chol-T were particularly effective, achieving up to 93.4% gene knockdown at the 30 nM siRNA 
concentration. The non- pegylated and pegylated cationic liposomes that have been formulated 
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1.1 AN OVERVIEW OF GENE THERAPY AND RNA INTERFERENCE 
 
The concept of gene therapy has been developed for the treatment of both inherited and acquired 
diseases. Many laboratories in biochemistry, medicine and pharmacy are focusing their research 
on gene therapy (El-Aneed, 2004). This research has now become quite broad. Gene therapy 
does not strictly refer to the treatment of a disorder by introducing a functional gene to replace a 
defective gene by gene transfer, but rather, it can now be defined by the introduction of nucleic 
acids, either RNA or DNA, which can be used to prevent or treat an inherited or acquired disease 
(El-Aneed, 2004; Robbins and Ghivizzani, 1998). Many genetic conditions, some forms of 
cancer and certain viral infections such as AIDS can be potentially treated with gene therapy (El-
Aneed, 2004).  
 
For many years, it was thought that RNA was a molecule that could function either as a 
messenger (mRNA) or form part of the translation machinery (tRNA, rRNA) (Brantl, 2002). 
After much research, it was found that RNA molecules are quite versatile and that they play 
important roles in many biological processes such as splicing, editing, protein export, among 





The use of small interfering RNA (siRNA) for gene therapy has attracted attention as a new 
therapeutic approach for the treatment of various diseases (Kim et al., 2010; Zhang et al., 2010). 
Over the past decade, much interest has been given to RNA Interference (RNAi) for analyzing 
mammalian gene functions, both in vitro and in vivo and for the silencing of gene expression 
(Kim et al., 2010; Leung and Whittaker, 2005). The phenomenon of RNAi involves a sequence-
specific gene silencing brought about by small double stranded RNA (dsRNA) molecules termed 
siRNA (Zhang et al., 2007). The siRNA consist of 21-23 nucleotides with a duplex region of 19 
base pairs (Kim et al., 2010). A characteristic feature of siRNA is the presence of a two 
nucleotide 3’ overhang which is recognized by the enzymatic RNAi machinery. This results in 
homology dependant target mRNA cleavage (Meister and Tuschl, 2004). 
 
The RNAi discovery occurred as a convergence of different experiments that were not related 
(Hammond, 2005). In the late 1980’s, RNAi was first discovered by plant biologists who found 
gene silencing pathways in plants and fungi brought about by transgene expression or viral 
replication, but the exact mechanism was not fully understood (Hammond, 2005; Zhang et al., 
2007). The groundbreaking discovery by Andrew Fire and Craig Mello in the late 1990’s showed 
that dsRNA could bring about gene silencing in Caenorhabditis elegans (Fire et al., 1998). Their 
studies showed that RNAi is an evolutionary conserved gene silencing mechanism and that 
interference of the targeted gene was more effective when using dsRNA as opposed to using 
either individual strand (Zhang et al., 2007). Since the discovery of RNAi, it is rapidly becoming 
the preferred method for gene function analysis. There are many advantages in using the process 
of RNAi over other therapeutic methods. These include a high specificity of the siRNA with low 
toxicity as is often observed in antisense methods and chemotherapy. Moreover, the siRNAs 
show a greater resistance to nuclease degradation as compared with antisense oligonucleotides 
therefore increasing the therapeutic effects of RNAi as compared to antisense therapy (Zhang et 





1.2 MECHANISM OF RNA INTERFERENCE (RNAi) 
 
RNAi functions naturally as a defence mechanism against viruses which produce dsRNA in the 
host cell when they are active and against transposons. The specific degradation of the mRNA 
during the RNAi process prevents the replication of the viruses (Elbashir et al., 2000). When 
siRNA is introduced, the RNAi process is initiated. The siRNA is produced from exogenous or 
endogenous long dsRNA (Kong et al., 2007). In an initiation step, the long dsRNA is identified 
by the endonuclease DICER. This endonuclease is a specific enzyme for dsRNA and cleaves the 
long dsRNA into the shorter siRNAs (Zhang et al., 2007)  The DICER enzyme has an N-
terminal RNA helicase domain, a Piwi, Argonaute, Zwille (PAZ) domain, two RNase III 
domains and a C-terminal dsRNA binding motif (Kim and Rossi, 2007). DICER is found 
complexed to the TAR-RNA binding protein (TRBP) (Aagaard and Rossi, 2007). The step that 
follows is referred to as the effector step. In this step, the siRNA is released from the DICER- 
TRBP complex and forms part of a nuclease complex called the RNA- induced silencing 
complex (RISC) (Zhang et al., 2007; Hammond, 2005; Aagaard and Rossi, 2007). The RISC 
complex contains Argonaute 2 which is responsible for melting the ds siRNA and cleaves the 
target mRNA (Aagaard and Rossi, 2007). The cleavage of the ds siRNA results in the formation 
of an activated form of the RISC complex which contains a ss RNA molecule, being the anti-
sense strand of the siRNA (Hammond, 2005; Aagaard and Rossi, 2007). This ‘new’ single 
stranded RNA (ssRNA)- RISC complex then recognizes complimentary mRNA sequences, this 
recognition is guided by the anti-sense RNA strand within the activated RISC complex (Ryther et 
al., 2005; Aagaard and Rossi, 2007). This occurs by Watson-Crick base pairing in the cytoplasm 
(Elmén et al., 2005). The target mRNA is then cleaved between bases 10 and 11 relative to the 5’ 
end of the antisense siRNA by Argonaute 2 and, therefore, the translation of the target mRNA is 
inhibited (Hammond, 2005; Aagaard and Rossi, 2007). If the siRNA/mRNA duplex contains any 
mismatches, the target mRNA will not be degraded (Hammond, 2005). Therefore, it can be said 
that gene silencing is brought about as a result of translational inhibition (Zhang et al., 2007, 










RNAi can be initiated by short synthetic dsRNA molecules made up of 21-23 nucleotides in 
mammalian cells (Figure 1.2). These short RNA duplexes will be able to guide the cleavage of 
the complimentary mRNA sequence and hence, the corresponding protein production is stopped. 
The dsRNA can be introduced into the cytoplasm through the cleavage of long dsRNA by 
DICER to siRNA; chemically synthesized siRNA can be introduced into the cytosol which will 
bypass the DICER step; plasmids or viral vectors can be used which encode either of the two 
RNA strands or by action of endogenous microRNAs (miRNAs). The miRNA maturation is 
initiated by nuclear cleavage carried out by DROSHA RNase III into a 60-70 nucleotide 
intermediate. In all these mechanisms the activity of RISC is activated and the expression of the 
mRNA is inhibited. However, the introduction of siRNAs results in the degradation of the 
mRNA while miRNAs repress the translation of the target mRNA by partial complementarity. 
This mechanism by miRNAs may be responsible for some of the ‘off target’ effects which are 
observed in some cases (Masiero et al., 2006). Since RNAi results in transient sequence specific 
interference of gene expression, a new category of molecules, that are nucleic acid based, is 
created and has significant medical potential for the treatment of diseases (Thomas et al., 2007). 
It can be said that every human disease that results due to the activity of one or many genes 
should have the potential to be treated by RNAi based therapeutics (Aagaard and Rossi, 2007), 
some of these diseases are outlined in table 1.1.  Therefore, it has been said that in biology, the 
discovery of RNAi is one of the most important in recent years (Zhang et al., 2007; Hammond, 











Table 1.1 Examples of human diseases with potential targets for RNAi based therapeutics 
(Cheng et al., 2003) 
DISEASE mRNA TARGETED 




HIV p24 Gag, CCR5 
Cryptococcus neoformans CAP 59, ADE2 
Influenza Nucleoplasmid(NP), RNA transcriptase 
Human Papilloma virus E6, E7 
 
 
The ability to use synthetic siRNAs to induce RNAi in mammalian cells has stimulated interest 
in its therapeutic potential (Lu et al., 2009). If siRNA can be targeted to an oncogene, it can be 
used as a therapeutic agent in cancer therapy (Gao and Huang, 2008). The growing potential of 
RNAi for the treatment of genetically based and infectious diseases will not be able to achieve its 
goals without resolving the issue of gene delivery (El-Aneed, 2003). The success of gene therapy 
is greatly dependant on the delivery vector (Gao and Huang, 2008). One of the main objectives 
of gene therapy is the transfer of the genetic material to the targeted cells. The gene therapy 
application influences the aim of the delivery system (El-Aneed, 2003). The question of delivery 
still remains the biggest hurdle which has to be solved in order to avoid any setbacks during 




1.3  GENE DELIVERY VEHICLES 
 
In order for the effectiveness of RNAi to be achieved, the siRNA needs to reach the cytoplasm of 
the target cell. The efficient delivery of siRNA still remains a main challenge for RNAi based 
therapeutics. This obstacle arises due to the properties of siRNA. Firstly, the naked siRNAs have 
a half life time of less than an hour in human plasma (Zhang et al., 2007). Due to the size of the 
siRNA, which is usually 21 nucleotides in length, circulating siRNAs are excreted by kidneys 
quite rapidly. Furthermore, the naked siRNA is highly charged and cannot penetrate the lipid 
membranes of cells and lastly, circulating naked siRNAs are susceptible to degradation by the 
enzyme RNase A and nucleases (Lu et al., 2009; Tseng et al., 2009). Due to these hurdles, there 
is a need to develop siRNA delivery systems that are capable of efficiently introducing siRNA 
into the cytoplasm (Han et al., 2008).  
 
Many gene delivery systems that exist to date were originally designed for the delivery of DNA 
and many have been adapted for the delivery of siRNA, since the barriers to delivery are similar 
(Lu et al., 2009, Thomas et al., 2007). The differences that exist between DNA and siRNA 
include the size and electrostatic charge of the DNA which is much larger than that of siRNA 
(typical molecular weights are 1600kDa and 15kDa, respectively) as well as their site of action 
(Lu et al., 2009). Nuclear entry is required for DNA in order for it to access the transcriptional 
machinery whereas siRNA is a post-transcriptional process and mediates its effect in the 
cytoplasm of the target cells therefore, the delivery of siRNA may be more easily achieved as 
compared to DNA delivery in non-dividing cells (Lu et al., 2009; Thomas et al., 2007). These 
differences could affect the function and the efficiency of the gene delivery system; however, 
since DNA and RNA share chemical similarity, their delivery barriers are likely to be similar. 
Both DNA and siRNA need to cross the cellular membrane and should be able to successfully 
escape degradation in the lysosome (Thomas et al., 2007). The success of gene therapy is 
dependent on the gene delivery vehicle, which is divided into two categories, namely, viral and 
non-viral vectors, both of which shall be discussed briefly. 
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1.3.1 Viral Vectors 
 
Viral vectors are viruses that have been modified such that they are replication defective. This 
allows nucleic acids to be introduced into the cell via the natural mechanisms of viral cell 
infection (Masiero et al., 2007). Viral vectors are considered as one of the most efficient gene 
transfection agents due to their transduction efficiency and also the ability of some viral vectors 
to infect non-dividing cells (Ramon et al., 2008). Retroviruses, adenoviruses and adeno-
associated viruses are some of the different types of viral vectors that can be used for siRNA 
delivery.  Within many of the viral vectors, a short hairpin RNA (shRNA) will be encoded which 
is found between polymerase (pol) III promoter (H1 or H6) and a transcription termination site 
(Masiero et al., 2007). Following transcription, the RNA folds which results in the formation of a 
stem-loop structure which is initially processed in the nucleus and thereafter within the 
cytoplasm. The shRNA is then converted to a small RNA molecule which is approximately 21 
nucleotides in length. This small RNA molecule is capable of inducing RNAi (Ramon, et al., 
2008). 
 
Retroviral vectors are based on the murine stem cell virus or Moloney murine leukemia virus 
(Masiero et al., 2007). They are developed by replacing the viral genes with the therapeutic 
genes. The delivery of foreign genetic material using the retroviral vectors was first described in 
1981 (El-Aneed, 2004). Retroviruses are small RNA viruses that have a DNA intermediate. They 
are capable of entering a variety of host cells and are capable of integrating into the host genome. 
This can only be done in replicating cells. A disadvantage with the use of these retroviral vectors 
is that accidental random integration in the host genome which may result in deleterious effects 
such as activation of proto-oncogenes through insertional mutagenesis (Seth, 2005). 
Adenoviruses are double stranded DNA viruses that are capable of infecting dividing and non-
dividing cells. The adenoviral vectors are developed by replacing the viral E1 gene with the 
therapeutic genetic material. Immunological responses to the adenoviral vector is a limitation 
which can be potentially harmful to the patients. Adeno-associated viruses are single stranded 
DNA viruses. Their two viral proteins, Rep and Cap, are removed which makes them defective 
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and allows them to be used in gene therapy. The adeno-associated viral vectors are also capable 
of infecting dividing and non-dividing cells. The main limitation is that the adeno-associated 
viral vectors require helper viruses (adenoviruses, herpes simplex virus) for adeno-associated 
virus production, which may result in contamination of the adeno-associated viruses during 
production (Seth, 2005).   
 
Viral vectors have a high gene transfer efficiency and are still considered as a powerful method 
of gene transfer. However, as mentioned above, there are many limitations that exist when using 
viral vectors. Some of the viral vectors have a very small loading capacity, large scale production 
is difficult and they pose severe safety risks because of their oncogenic potential, and 
immunogenic and inflammatory effects. These prevent viral vectors from being administered 
repeatedly. In order to overcome these limitations, non-viral vectors have emerged as an 
attractive alternative to viral vectors (Gao and Huang, 2008) 
 
1.3.2 Non- Viral Delivery Systems 
 
Although the use of viral vectors has shown to result in higher transfection efficiency in most 
cell lines tested, non-viral vectors have attracted more attention for their use as gene delivery 
vehicles (Akhtar and Benter, 2007). This can be attributed to the many advantages associated 
with non-viral delivery vehicles. These advantages include the ease of synthesis, unrestricted size 
of gene material, low immune response and the potential safety benefits (Zhang et al., 2007). 
The aim of non-viral gene therapy is to mimic viral methods to overcome the cellular barriers but 
minimize toxicity associated with viral approaches (Balicki and Beutler, 2002). Physical and 
chemical methods can efficiently introduce siRNA to mammalian cells in vitro, but there are a 
few in vivo delivery systems that exist. Physical methods that have been studied for siRNA 
delivery include hydrodynamic injection, electroporation and the gene gun method. The 
chemical, synthetic approaches that have been studied include the use of cationic lipids and 
polymers, as well as nanoparticles. These non-viral vectors shall be discussed briefly. 
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1.3.2.1 Physical Non-Viral Delivery Approaches 
 
1.3.2.1.1 Hydrodynamic Injection 
 
The hydrodynamic approach involves the rapid injection of siRNA in a large volume of 
physiological buffer (Gao and Huang, 2008; Davis, 2002). This quick injection results in a 
transient increase in the venous pressure and results in the entry of the nucleic acid primarily to 
the liver (Rozema and Lewis, 2003). Song et al. (2003), introduced siRNA by utilizing many 
hydrodynamic injections which resulted in 90% knockdown of expression of the endogenous Fas 
receptor in hepatocytes (Song et al., 2003). McCaffery et al. (2002), used hydrodynamic 
injection to transfect the luciferase gene with siRNA or shRNA in mice which resulted in 
reduced expression of the luciferase gene in the liver (McCaffrey et al., 2002). Due to the 
invasive nature of this technique, as well as the generation of high pressure in the vascular 
system due to the injection of large volumes which could result in heart failure, the use of 
hydrodynamic injection is currently not viable for human clinical applications at this point 




The electroporation technique was designed to allow for the penetration of molecules into a cell 
due to the application of an electric field. DNA and RNA can be effectively introduced using this 
method. Electroporation involves two stages: in the first stage, an electric shock creates pores in 
the cell membranes and in the second stage, electrophoresis is applied which allows the 
negatively charged molecules to enter the cytosol (Ramon et al., 2008). Electroporation was used 
by Akaneya and co-workers (2005) to deliver siRNA to the brain which resulted in inhibiton of 
gene expression of the GluR2 and cox-1 genes (Akaneya et al., 2005). Targeting can be achieved 
by using electroporation but this technique requires electrodes to be inserted into the target area 
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and, therefore, for this to be achieved, invasive procedures are required to expose the target 
tissue for transfer, which limits the application of electroporation (Vandenbrouke et al., 2008). 
 
1.3.2.1.3. Gene Gun Method 
 
The gene gun method involves the firing of siRNA coated gold particles. This allows for the 
direct delivery of nucleic acids to the tissue or cells. The gene gun approach allows for siRNA to 
directly penetrate the cell membrane and enter the cytoplasm which is done by bypassing the 
endosomal compartment (Ramon et al., 2008). Kim and colleagues (2005) made use of the gene 
gun method for the delivery of siRNA in vivo. This was done to enhance a vaccine’s 
effectiveness (Kim et al., 2005). The gene gun approach can only be local and the tissues are not 
deeply penetrated by the nucleic acids using this approach (Ramon et al., 2005; Niidome and 
Huang, 2002). 
 
In these limited applications, it is possible for the siRNA to be delivered directly to the target 
sites, however, in most applications, a carrier system is necessary for the protection of the siRNA 
against degradation and to guide in the uptake of the siRNA by the target cell (Almofti et al., 
2002). 
 
1.3.2.2 Chemical Non-Viral Delivery Approaches 
 
The carrier systems that exist are synthetic systems that usually contain a cationic component, 
for example, cationic lipids, cationic polymers and cationic peptides (Almofti et al., 2002). The 
cationic component binds to the negatively charged siRNA. A chemical non-viral delivery vector 
can also include specific binding to the surface of the cell, cellular entry, escape from the 
endosome, among others (Balicki and Beutler, 2002). 
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1.3.2.2.1 Polymer Nanoparticles 
 
Polymer nanoparticles have been used for the delivery of siRNA. These nanoparticles can be 
synthetic from a number of different polymers, which include poly-ethyleneimine (PEI), chitosan 
as well as PEG-branched polymers. These polymer nanoparticles are polycations or they contain 
polycation block polymers which are capable of forming interpolyelectrolyte complexes (IPECs) 
or block ionomer complexes (BICs), respectively with the siRNA (Zhang et al., 2007). IPEC 
systems that are being used are made up of complexed polycations for example, poly-L-lysine 
and PEI together with nucleic acids (DNA and RNA). Self assembly of these complexes occurs 
due to the strong electrostatics between the oppositely charged polyelectrolytes which results in 
prevention of enzymatic degradation of the incorporated nucleic acid in the blood stream 
(Niidome and Huang, 2002). BICs have been recently synthesized which could overcome the 
problems of circulation which is present in conventional systems. Poly-ethylene oxide (PEO) and 
poly [(N-2-hydroxypropyl)methacrylamide] (PHPMA) are usually chosen as the neutral block. 
They are hydrophilic and non-immunogenic. The cationic segments are synthetic amine 
polymers which bind to the nucleic acid (Zhang et al., 2007). 
 
(a) Polyethylene imine (PEI) 
 
Polyethylene imine (PEI) consists of a series of synthetic polymers with a very high cationic 
charge. This positive charge allows PEI to form complexes with the nucleic acids and condense 
them. This tight compaction together with their buffering capacity in endosomes and lysosomes 
protect the nucleic acids against being degraded. Branched PEI (25 and 800kDa) and linear PEI 
(25kDa), have been utilized as transfection agents. Efficient in vitro and in vivo transfection was 
shown using branched PEI (800 kDa) linked to a ligand. Much attention has been given to linear 






Chitosan has gained much interest in recent years as a safe and cost effective non-viral based 
delivery system for gene materials. Chitosan has shown low levels of immunogenicity and 
toxicity, very high levels of biodegradability and a very high positive charge which, through 
electrostatic interactions, can form complexes with the negatively charged nucleotides (El-
Aneed, 2004). There have been many studies on chitosan as a carrier for DNA delivery. The 
results have shown efficient expression of the reporter genes in vitro and in vivo and, therefore, 
have increased interest in their use as a carrier for siRNA. siRNA delivery using chitosan may 
have first been studied by Katas and co-workers in 2006 (Katas and Alpar, 2006). A novel 
chitosan mediated siRNA delivery system was developed by Howard et al. (2006) for RNAi in 
vitro and in vivo. The results showed knockdown was evident of the endogenous enhanced green 
fluorescent protein (EGFP) in human lung carcinoma cells and murine macrophages (72.9% and 
89.3% reduction in expression, respectively) (Howard et al., 2006).   
 
1.3.2.2.2  Liposomes 
 
The dispersion of phospholipids in an aqueous medium results in the spontaneous formation of 
closed structures consisting of phospholipid bilayer membranes that encapsulate an aqueous 
cavity. This system is referred to as a liposome. Liposomes, therefore, are referred to as 
vesicular, spherical shaped systems which can be produced from cholesterols, sphingolipids, 
glycolipids, long chain fatty acids and even membrane proteins (Samad et al., 2007). Bangham 
and co-workers first discovered liposomes approximately 40 years ago following the initial 
publication of their use in 1965. The practicality and the value of the use of liposomes has been 
since identified and improved and are at present useful tools in science (Bangham, 1980; Samad 
et al., 2007; Balazs and Godbey, 2010). A variety of molecules including small drug molecules, 
nucleotides and proteins have been incorporated into liposomal systems and delivered to cells. 
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Many liposomal formulations have been commercialized to date namely lipofectamine, fugene, 
among others.  
 
Liposomal reagents can be divided into four categories, namely, conventional or anionic 
liposomes, cationic liposomes, stealth liposomes and targeted liposomes (Figure 1.3). The use of 
an anionic liposomal system requires entrapment of the nucleic acid in the aqueous space of the 
liposome. Minimal use of this type of system has occurred over the years, which could be 
attributed to the variable encapsulation efficiency and also since the process is time consuming 
(Ramon et al., 2008; Singh, 1998).  
 
Liposomal targeting can be achieved by introducing targeting moieties to the liposomal 
composition which can recognize and bind to target cells (Immordino et al., 2006). Targeting 
moieties include ligands, proteins, peptides, antibodies, polysaccharides, glycolipids, 
glycoproteins and lectins (Kelly et al., 2010). A targeting system that is commonly used is the 
transferrin (Tf) receptor (TfR) for binding, as well as cellular entry because these receptors are 
over expressed in many tumour cells (Dass and Choong, 2006). A major advantage in the use of 
targeted liposomes is the selective targeting of specific tissues or cell types which can result in an 
increase in the amount of nucleic acid delivered to the target cell (Immordino et al., 2006, Kim et 
al., 2009). Cationic liposomes and stealth liposomes will be discussed below. 
 
The unique advantages associated with the use of liposomes over other vectors include a diverse 
range of morphologies, composition, ability to envelope and protect many types of therapeutic 
molecules, low toxicity, low immunogenic response, low cost as well as different release 






Figure 1.3: Four classes of liposomes defined by their functionality and used for gene delivery  
         (Adapted from Lasic, 1997).  
 
1.2.2.2.1  Cationic Liposomes  
 
The delivery of nucleic acids using cationic liposomes was pioneered by Felgner and co- workers 
in the late 1980s who developed cationic liposomes consisting of a monovalent cationic lipid    
N-[1-(2,3-dioleyloxy) propyl]- N,N,N- trimethylammonium chloride (DOTMA)  and the neutral 
lipid dioleoylphosphatidylethanolamine (DOPE) in a 1:1 ratio (Felgner et al., 1987). Since this 
invention, many other cationic liposome formulations have been synthesized and are available 
commercially. These include DOTMA (Figure 1.4), N-[1-(2,3-dioleoyloxy) propyl]- N,N,N- 
trimethylammonium methyl sulphate (DOTAP) (Figure 1.5), 3[N-(N’,N’- dimethylamino-
ethane)- carbamoyl] cholesterol (DC-CHOL) (Figure 1.6), among others (Miller, 1998). Cationic 
lipids contain the same general structure. They consist of a hydrophobic lipid anchor, a linker 
group for example an ester, amido or carbamate, and a positively charged head group, which in 



















Figure 1.5: Structure of DOTAP (www.hindawi.com/journals/jdd/2011/326497) 
 
The structure of DOTMA consists of two unsaturated oleoyl chains which are linked to a three 
carbon skeleton of glycerol via ether bonds and a head group consisting of a quaternary amine. 
In the late 1980s, DOTMA showed a higher gene transfer efficiency as compared to other gene 
transfer methods (Balazs and Godbey, 2010). The relative simplicity of preparing complexes 





vectors for gene therapy. The initial success with DOTMA for in vitro transfection resulted in the  









Figure 1.6: Structure of DC-CHOL (Martin et al., 2005). 
 
Leventus and Silvius synthesized DOTAP in 1990 (Leventis and Silvius, 1990). The structure of 
DOTAP consists of two oleoyl chains that are linked to a glycerol backbone with a quaternary 
amine head group. The only difference that exists between the structures of DOTAP and 
DOTMA is that of the linker bond, that is, the ester bond linkage between the backbone and the 
chains in DOTAP rather than the ether bond. Ester bonds are hydrolysable, therefore, it was 
hypothesized that the introduction of ester bonds could reduce cytotoxicity and make the lipid 
biodegradable. Studies showed that there were minimal differences between DOTAP/ DOPE and 
DOTMA/DOPE transfection activities and cytotoxicity. At pH 7.4, DOTAP becomes completely 
protonated and is usually combined with a helper lipid, which is now the case for most cationic 
liposome formulations (Balazs and Godbey, 2010). 
 
DC-CHOL was synthesized in 1991 by Gao and Huang and consists of a cholesterol moiety 




Huang, 1991). Cholesterol was introduced due to its biocompatibility as well as the stability it 
imparts to the lipid membranes. This idea was supported by the increased transfection efficiency 
when using this liposome. The cytotoxicity associated with DC-CHOL was much lower than that 
of DOTMA in certain cell lines. Unlike DOTMA and DOTAP which contain fully charged 
quaternary amines, DC-CHOL in a 1:1 molar ratio with DOPE, has a tertiary amine function and 
at a pH of 7.4, is only charged on approximately 50% of the surface of the liposome. Due to this 
feature, the aggregation of lipoplexes with DC-CHOL is said to be reduced which, therefore, 
leads to higher transfection efficiencies (Balazs and Godbey, 2010).    
 
Cationic liposomes are formulated with positively charged lipids, and, therefore, are physically 
associated with the nucleic acid and do not require encapsulation. These physical associations 
occur through electrostatic interactions between the positive charges of the cationic liposome and 
the negative charges of the nucleic acid which exist due to the presence of phosphate groups in 
the nucleic acid (Ramon et al., 2008). Complexes between the cationic liposome and the nucleic 
acid are easily prepared by simply mixing the two components and incubating for a short period 
of time, which results in the nucleic acid becoming associated with the outer surface of the 
liposome. This method is quick, simple and does not require the separation of the liposome 
bound material (Lonez et al., 2008). The positive charge of the head group also allows for the 
binding of the lipoplex to the negatively charged components that exist on the cell membrane 
before uptake which results in improved delivery of the nucleic acid (Lonez et al., 2008).  
 
Cationic liposomes are formulated with the cationic lipid together with the neutral lipid DOPE. 
DOPE is usually incorporated into the liposomal formulation due to its membrane destabilizing 
effects at a low pH which assists in escape from the endosome during endocytosis (Farhood et 
al., 1995). 
   
A major disadvantage in the use of cationic liposomes is their uptake by macrophages in the 
mononuclear phagocyte system (MPS) and their removal from blood circulation. This problem 
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can be circumvented by the introduction of poly-ethylene glycol (PEG) which coats the 
liposomal surface and, in doing so, increases the circulation time of the liposome. 
 
1.2.2.2.2  Stealth Liposomes 
 
With respect to the above mentioned hurdle, many strategies have been tested where the surface 
of the liposome can be coated with an inert molecule which results in the formation of a spatial 
barrier (Immordhino et al., 2006). In initial studies, the surface of the liposome was modified by 
introducing monosialganglioside (GM1) which increased the hydrophilicity of the liposome 
(Gabizon and Papahadyopoulous, 1988; Allen et al., 1989). These liposomes remained in blood 
circulation for many hours as the MPS uptake was reduced (Immordhino et al., 2006). However, 
there were problems associated with the availability of GM1 which resulted in the search for a 
substitute and, in turn, led to the development of the introduction of poly-ethylene glycol (PEG) 
into formulations (Allen, 1994). 
 
PEG is commonly used as a polymeric steric stabilizer (Immordhino et al., 2006). PEG is a 
linear polyether diol which is soluble in aqueous and organic media, has a low toxicity and 
immunogenicity, is biocompatible, and exhibits good excretion kinetics (Immordhino et al., 
2006). PEG can be introduced onto the liposomal surface in many ways, but the most commonly 
used method involves the anchoring of PEG via a cross linked lipid, that is, 
distearoylphosphatidylethanolamine-PEG (DSPE-PEG) into the membrane of the liposome 
(Allen et al., 1991) (Figure 1.7). The presence of DSPE-PEG improves their stability, inhibits 
protein adsorption onto the liposomal surface and opsonization in vivo which prevents the 
recognition of the liposome by the reticoendothelial system (RES). This enhances the circulation 







   
 
Figure 1.7: Structure of DSPE-PEG (www.avantipolarlipids.com). 
 
There are many advantages that exist with pegylated liposomes, with the most significant being 
the large decrease in MPS uptake and increased circulation time in blood which results in their 
increased distribution. Interbilayer attraction due to the presence of Van der Waals forces is 
overcome due to the presence of PEG which avoids the aggregation of the liposomes, and, hence, 
the formulation is stabilized (Immordhino et al., 2006).  
 
The properties of the PEG molecule that is grafted onto the liposomal surface determines the 
behavior of the stealth liposomes. Two regimes proposed by deGennes describe the attachment 
of the PEG molecules onto the liposomal surface (deGennes, 1980). They are the brush and 
mushroom regimes, and are so named depending on the grafting density (Figure 1.8). The 
surface coverage and the distance between the grafting sites are determined by the graft density 
and the molecular mass of PEG (Immordhino et al., 2006). The presence of a single elongated 
PEG molecule on the liposomal surface is referred to as the mushroom regime. The brush regime 
refers to the presence of more than one elongated PEG molecule, regardless if they exist as 
individual ‘mushrooms’ or are made up of a dense network of entangled chain. The molecular 
brushes are said to sterically protect the liposomes from biological interactions. This occurs by 
sterically stabilizing the liposomes or preventing opsonization. The mechanisms that have been 
suggested for this stabilization include ‘repulsion’ as a result of polymer chain constriction, the 
formation of a molecular cloud which protects the surface from opsonins or the formation of a 
















Figure 1.8: Schematic representation of the brush and mushroom regimes of PEG (Adapted 
from Immordhino et al., 2006; Narainpersad, 2009). 
 
A major characteristic of stealth liposomes is their increased circulation time which occurs 
regardless of the surface charge or the presence of a stabilizing agent. The hydrophilic shell that 
exists in PEG molecules has the ability to prevent aggregation between liposome particles as 
well as to reduce interactions between the liposome and biological fluids. This occurs not only 
because of the molecular mass and the uniformity of the PEG molecule, but is also due to the 
conformational flexibility of the polymer (Torchillin et al., 1994). The circulation longevity of 
pegylated liposomes depends on the amount of grafted PEG as well as the length and molecular 








1.4  ENDOCYTOSIS   
 
The first step in the delivery of nucleic acids by cationic liposomes is the entry of these 
complexes into the cells (Miller, 1998). There are three models for the interaction of cationic 
liposomes with mammalian cells, they are (i) fusion of the liposome with the cell or 
destabilization of the endosome, (ii) direct fusion of the liposome with the plasma membrane or 
(iii) transfer of the lipoplex across the cell membrane into the cytosol (Wrobel and Collins, 
1995). 
 
 It was initially proposed that the primary mechanism for the entry of liposomes into the cell 
involved the direct fusion between the liposome and the cell membrane. This was based on the 
observation by Felgner and co-workers on the interaction between free liposomes and the plasma 
membrane (Felgner et al., 1987). However, studies have shown that the cationic liposome: 
nucleic acid complexes do not enter the cell by direct fusion but rather, through slow 
endocytosis. This was first proposed by Behr et al. in 1993 and was later observed by Zabner et 
al. in 1995. Electron microscopy was utilized by Zabner et al. to follow cell entry of the 
complexes (Zabner et al., 1995). 
 
Once siRNA: cationic liposome complexes are prepared, the net negative charge of the siRNA is 
‘hidden’ and the overall positive charge of the lipoplex facilitates its binding to the cell 
membrane, which is negatively charged (Figure 1.9). Once the lipoplexes are bound to the cell, 
the complexed siRNAs are taken up by endocytosis and are located within the endosome (Figure 





Figure 1.9: Schematic representation of the acceptance of the cationic liposome by 
mammalian cells (www.jpp.krakow.pl/.../articles/05_article.html) 
 
 
The intracellular trafficking of the siRNA begins in the early endosome. The early endosomes 
fuse with sorting endosomes, which transfers their contents to late endosomes (Dominska and 
Dykxhoorn, 2010). The late endosomes are acidified (pH 5-6) and their content is then 
transferred to the lysosomes. The lysosomes are then further acidified (pH~4.5). To prevent 
degradation of the siRNA in the lysosomes, the siRNA needs to escape from the endosome 
(Dominska and Dykxhoorn, 2010). The transfection agent must have the ability to disrupt or fuse 
with the endosomal membrane in order to deliver the siRNA to the cytosol (Rozema and Lewis, 
2003). The most common strategy used to achieve this criterium is the incorporation of DOPE 
into the liposomal formulation. DOPE is said to promote polymorphic changes of the lipids by 
promoting the formation of the reverse hexaganol phase from the lamellar liquid crystal phase 
(Miller, 1998). DOPE, therefore, can be used for the disruption of the endosome. Electrostatic 
interaction between the membranes of the endosome and the cationic liposome results in a “flip-
flop” of the negatively charged lipids of the endosome that faces the cytosol which diffuses into 
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the complex (Miller, 1998). Here, they form neutral ion pairs with the cytofectins which results 
in the disruption of the lipoplex and, therefore, the nucleic acid diffuses into the cytosol (Miller, 












Figure 1.10: Illustration of endocytosis of siRNA: cationic liposome complex (Lu et al., 2009) 
 
1.5  OUTLINE OF THESIS 
 
Gene therapy using siRNA has emerged as a promising approach for the treatment of various 
diseases including cancer and genetic disorders. However, a major challenge lies in the delivery 
of siRNA where intracellular and extracellular barriers need to be overcome. To date, many non-
viral vectors have been studied for the delivery of siRNA (Kim et al., 2010). In this thesis, the 




suggested that cationic liposomes generally have a poor circulation time in the blood system. The 
introduction of PEG is said to increase the circulation time of the cationic liposome and, in doing 
so, the amount of the siRNA introduced into the cell can be increased (Vandenbrouke et al., 
2008). 
 
Cationic liposomes were prepared either with cytofectin Chol-T or MSO9, the neutral co-lipid 
DOPE and varying degrees of pegylation (0, 2, 5 mole percent). These liposomes were 
characterized using Transmission Electron Microscopy. Complexation of the siRNA with the 
cationic liposomes was determined using the gel retardation assay, and the ability of the cationic 
liposomes to protect the siRNA from nuclease degradation was studied with the nuclease 
protection assay. 
 
Cytotoxicity and transfection studies were carried out using the HeLa tat luc cell line, a human 
cervical cancer cell line that stably expresses the firefly luciferase gene. These assays are 
outlined in chapter 4. The efficiency of transfection was determined using the luciferase assay 
where luciferase gene knockdown was determined. 
 
A further aim of this study was to investigate the effect of pegylation on the efficiency of 
cationic liposome mediated siRNA delivery to the HeLa tat luc cell line in culture. The 
introduction of PEG to the liposomal formulation was carried out to enhance the circulation time 
and prevent opsonization of the liposomes, which would result in a more efficient delivery of the 
siRNA. Although pegylation is known to increase the circulation times of lipoplexes under in 
vivo conditions, it is also believed to adversely affect the cellular uptake of the lipoplexes. The 
introduction of the PEG moiety to the liposomal surface may partially mask the cationic charges 
close to the liposome bilayer adversely affecting siRNA: liposome charge-charge interactions. In 
this study, two related cytofectins differing in spacer arm length have been compared for siRNA 
transfection efficiency and also, the cellular uptake of siRNA promoted by liposomes that are 
pegylated up to 5 mole percent is being investigated by measuring luciferase gene knockdown in 
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the HeLa tat luc cells in culture. These studies will facilitate the development of cholesteryl 





























This chapter focuses on the synthesis of six different cationic liposomes formulated with either 
cytofectin Chol-T or MSO9. All liposomes were formulated with the neutral helper lipid DOPE. 
Different mole percentages of distearoylphosphatidylethanolamine polyethylene glycol 2000 
(DSPE-PEG2000), (0, 2 and 5 mole percent) were also incorporated into the formulation. 
 
Liposomes are defined as vesicular structures that are formed as a result of self assembly of 
dissolved lipids. These lipids interact with each other in a manner that is energetically favourable 
and results in these vesicles having one or more bilayers of the amphipathic lipid which 
encapsulates an aqueous compartment (Riaz, 1996; MacLachlan, 2007; Balazs and Godbey, 
2010).  
 
Upon formation of the liposomes, the lipids associate such that bimolecular leaflets are formed. 
These leaflets are characterized by the hydrophobic tails which face each other and the 
hydrophilic head groups that face the aqueous solution. At this point in the assembly, the 
formation of the bilayer still remains energetically unfavorable. This is due to the hydrophobic 
component of the lipid which is still in contact with the aqueous medium. This problem is 
overcome when the bilayer membrane, during its formation, curves upon itself and results in the 













Figure 2.1: Structure of a typical liposome with the lipid bilayer and aqueous compartment 
(www.grin.com/object/external_document.256998/ ) 
 
Liposomes are not rigid structures but are fluid entities which are versatile assemblies.  Due to 
their dynamic preparation and the ease with which they can be manipulated, liposomes have 
been used for drug and gene delivery. Liposomes present unique advantages which include their 
range of diverse morphologies, their ability to envelope therapeutic biomolecules, among others. 
Therefore, they have been applied in chemical and biochemical studies, cosmetics, drug and gene 
delivery (Chonn and Cullis, 1995; Balazs and Godbey, 2010). 
 
The lipid molecules that are utilized in liposomes contain a hydrophilic head group with a 
hydrophobic hydrocarbon tail that are linked via a backbone linker. The cationic lipids attain 
their positive charge generally due to the presence of amines. This positive charge allows for the 







The preparation of liposomes can be carried out using several methods. All these methods have a 
common step which involves the evaporation of the organic solvent in which the lipid molecules 
are dissolved (Singh, 1998). These methods can be classified as follows: 
 
i. The original hand-shaken preparation producing multilamellar vesicles 
(Bangham et al., 1965) 
ii. Sonication to prepare small unilamellar vesicles (SUVs) (Johnson et al., 1971) 
iii. Extrusion through filters to form large unilamellar vesicles (LUVs) or SUVs (Lasic, 
1997) 
iv. Homogenisation for mass production of liposomes (Lasic, 1997) 
v. Ethanol injection technique (Batzri and Korn, 1973; Campbell, 1995) 
vi. Ether injection technique (Deamer and Bangham, 1976)   
vii. Detergent depletion (Torchilin, 2003) 
viii. Reverse phase evaporation technique (Szoka and Papahadjopoulos, 1978) 
ix. Thin lipid film hydration (Gao and Huang, 1991) 
The method of Gao and Huang was adapted and used for the preparation of the cationic 
liposomes used in this study. 
 
The cationic liposomes are usually formulated with cationic lipids together with a neutral helper 
lipid which, in most cases is DOPE (Figure 2.2). DOPE is said to act as a fusogenic lipid which 
allows fusion of the complexed nucleic acid to the target cell as well as aiding in escape from the 
endosome (Farhood et al., 1994). 
 
Due to the ease of synthesis of liposomes, it is quite simple to modify the liposomal surface. One 
of these modifications involves the introduction of polyethylene glycol. Pegylation is said to 
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prevent the liposome complexed nucleic acid from aggregating in the blood as well as 








Figure 2.2: Structure of neutral helper lipid, DOPE (Lv et al., 2006) 
 
Liposomes exhibit a diverse range of morphologies that depend on the lipid mixtures in the 
aqueous medium and their assembly (Balazs and Godbey, 2010). Liposomes are classified on the 
basis of their size as well as the arrangement and number of lipid bilayers present. Multilamellar 
vesicles (MLV) are easily prepared by hydrating the lipid film. These vesicles are large 
structures that are made up of multiple concentric bilayers. The bilayers are separated by the 
presence of small aqueous compartments (MacLachlan, 2007). The multilamellar vesicles are 
hundreds of nanometers in diameter. Sonication of the multilamellar vesicles results in the 
formation of small unilamellar vesicles (SUV). The size range of these vesicles is between 20- 
200 nm in diameter. Unilamellar vesicles are analogous to the eukaryotic cell membrane and are 
characterized by the presence of a single bilayer membrane. This membrane encapsulates an 
aqueous solution which separates it from the external solution (Samad et al., 2007). Large 




This chapter focuses on the preparation of cationic liposomes utilizing novel cationic cholesterol 
derived cytofectins. These liposomes were characterized using transmission electron microscopy 
and their size and lamellarity were determined.      
 
2.2 MATERIALS AND METHOD 
2.2.1 MATERIALS 
 
Cationic cholesterol derivatives Chol-T and MSO9 were prepared in the department of 
Biochemistry, University of KwaZulu- Natal, Westville campus. DOPE was purchased from 
Sigma Chemical Company (St. Louis, USA). Polyethylene glycol2000 (DSPE-PEG2000) was 
purchased from Avanti Polar Lipids (Alabaster, USA).  2-[4-(2-hydoxyethyl)-1–piperazinyl] 
ethanesulphonic acid (HEPES) was purchased from Merck (Darmstadt, Germany). Ultrapure 
water (Milli-Q50) was used throughout. All other chemicals were of analytical grade. 
 
2.2.2 METHOD 
2.2.2.1 Synthesis of Cationic Cholesterol Derivatives 
 
2.2.2.1.1 Preparation of Cationic Cholesterol Derivative Chol-T 
 
The Chol-T used in this study was previously synthesized and the synthesis shall be briefly 
described. The preparation is represented in Figure 2.3. 
 To a solution of cholesteryl chloroformate (90 mg, 0.2 moles) in 1 ml dichloromethane was 
added 3- dimethylaminopropylamine (62.8 l, 0.11 moles). Following an hour at room 
temperature, the solvent (dichloromethane and excess 3-dimethylaminoproylamine) was 
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removed by rotary evaporation in a Büchii Rotavapor-R.  The resultant residue was dissolved in 
absolute ethanol and allowed to crystallize overnight at - 4°C. The resulting product was then 
recrystallized and filtered under dry nitrogen gas. This was followed by further drying by rotary 





















2.2.2.1.2  Preparation of Cationic Cholesterol Derivative MSO9 
 
MSO9 was synthesized in four steps with the first being the preparation of 
cholesterylformylhydrazide. Each of these four steps shall be discussed briefly as described by 
Singh and Ariatti (2006), and is illustrated in Figure 2.4. 
 
(a) Cholesterylformylhydrazide (MSO4) 
To a solution of hydrazine (240 mg, 7.5 mmole) in chloroform: methanol (3:0.6 ml) was added a 
solution of cholesterylchloroformate (1.13 g, 2.5 mmole) in chloroform. This was carried out 
with stirring at 0°C. Following 24 hours at room temperature, the solution was concentrated in 
vacuo which was followed by the recrystallization of the resulting crystalline mass from 
chloroform: methanol (4:1 v/v) to yield the product. 
(b) Cholesterylformylhydrazidehemisuccinate (MSO8) 
MSO4 (89 mg, 0.2 mmole) and succinic anhydride (20 mg, 0.2 mmole) was dissolved in 2 ml 
DMF: pyridine (1:1 v/v) and the reaction was maintained overnight at room temperature. The 
solvent was removed by rotary evaporation in a Büchii Rotavapor-R to yield the product of white 
crystals from absolute ethanol. 
(c) N- hydroxysuccinimide ester of cholesterylformylhydrazidehemisuccinate 
MSO8 (82 mg, 0.15 mmole), DCC (62 mg, 0.3 mmole) and N- hydroxysuccinimide (35 mg,    
0.3 mmol) were dissolved in 1 ml of DMF. The reaction was monitored by TLC (results not 
shown). After 48 hours, filtration was used to remove the dicyclohexylurea crystals. The solvent 
was removed by evaporation and the resultant crude product was dissolved in chloroform: water 
mixture (1:1 v/v). The water layer, containing excess N- hydroxysuccinimide, was removed. 
Following solvent evaporation, petroleum ether (60-80 °C) was utilized to extract the residue and 




(d) N, N-dimethylpropylamidosuccinylcholesterylformylhydrazide (MSO9) 
The N- hydroxysuccinimide ester of cholesterylformylhydrazidehemisuccinate (53 mg,        
0.083 mmole) and dimethylaminopropylamine (36 mg, 0.35 mmole) were dissolved in 15 ml 
water: pyridine: DMF (13: 7: 10 v/v/v) and TLC was used to monitor the reaction (results not 
shown). Purification of the product was carried out on four 60 F254 TL plates developed in a 
chloroform: methanol (95: 5 v/v) solvent system. 
      
2.2.2.2 Preparation of Cationic Liposomes 
 
The cationic liposomes were prepared using the method described by Gao and Huang (1991). 
The quantities of each lipid component of the cationic liposomes can be seen in Table 2.1. Six 
cationic liposomes were prepared containing either cytofectin Chol-T or MSO9.   
 
Each liposome preparation was composed of 2 moles of lipid. Each lipid component, which 
was first dissolved in chloroform to a concentration of 10 g/l, was deposited into its respective 
quick fit tube. The organic solvent was then removed using the Buchii Rotavapor-R rotary 
evaporator. This resulted in a thin lipid film on the inside of the quick fit test tube. This lipid film 
was then further dried, under vacuum, in a drying pistol for 30 minutes. The lipid film was then 
hydrated with sterile hepes buffered saline (HBS) (20 mM, pH 7.5). This was followed by 
vortexing and the liposome preparation was stored at 4°C overnight. Thereafter, the preparation 
was vortexed and sonicated for 5 minutes, which affords unilamellar liposomes. The liposomes 

















MOLAR RATIO (mol) 
 Chol-T MSO9 DOPE DSPE-
PEG2000 
Chol-T MSO9 DOPE DSPE-
PEG2000 
Chol-T 0.52 - 0.74 - 1 - 1 - 
2%PEG2000 
Chol-T 
0.52 - 0.72 0.11 1 - 0.96 0.04 
5%PEG2000 
Chol-T 
0.52 - 0.67 0.28 1 - 0.9 0.1 
MSO9 - 0.63 0.74 - - 1 1 - 
2%PEG2000 
MSO9 
- 0.63 0.72 0.11 - 1 0.96 0.04 
5%PEG2000 
MSO9 
- 0.63 0.67 0.28 - 1 0.9 0.1 
 
 
 2.2.2.2  Characterization of Liposomes by Transmission Electron Microscopy (TEM) 
Each liposome suspension was diluted to a 1:5 ratio with sterile HBS. The diluted liposome 
suspension (1 l) was placed on a formvar coated copper grid. To this, 1 l of 1% (w/v) uranyl 
acetate was added and allowed to dry for 2 minutes. Thereafter, the excess suspension was 
removed with filter paper and the grid was then immediately vitrified in liquid nitrogen. The 
vitrified samples were viewed using a GATAN cryotransfer device at -150 °C in a JEOL JEM 
1010 electron microscope (Tokyo, Japan). Images were captured digitally using a MegaView III 




2.3 RESULTS AND DISCUSSION 
 
2.3.1 Preparation of Cationic Liposomes 
 
The cationic liposomes were successfully prepared using the method described in section 2.2.1. 
Cytofectins, Chol-T and MSO9, were both previously successfully synthesized and have the 
same general structural features of most cationic lipids that are utilized to date, namely, a 
positively charged head group, a spacer arm, linker bond and a hydrophobic lipid anchor 
(Figures 2.5 and 2.6). Chol-T and MSO9 have similar chemical structural properties which 
include a cholesterol ring anchor, a carbamoyl linker bond and a dimethylamino head group. The 
difference between the two lipids lies in the length of their spacer arms where MSO9 has a 12 
atom spacer arm and Chol-T has a 6 atom spacer (Singh and Ariatti, 2006).  
 
The cholesterol anchor is said to impart better stability and also acts as an intercalator within the 
phospholipid molecules which results in the lowering of membrane permeability. Cholesterol 
also aids in membrane-protein interactions (Samad et al., 2007). The linker bond is a carbamoyl 
bond which is said to influence the biodegradability of the cationic lipid and also influences the 
chemical stability of the lipid (Singh and Ariatti, 2006). The length of the spacer arm may not be 
very critical, however, the cytotoxicity and transfection potential of the cationic liposome may be 
influenced by the nature and length of the spacer arm (Oh and Park, 2009). A longer spacer arm 
could reduce steric hindrance between the polar head group and the cholesterol ring system 
which would result in a better interaction between the cationic lipid and the nucleic acid (Singh, 
1998). The transfection activity and cytotoxicity of the cationic lipid may be influenced by the 
nature of the head group. Chol-T and MSO9 are monovalent cationic lipids and are able to 
condense nucleic acids less strongly as compared to multivalent cationic lipids, however, it has 
been said that a high number of positive charges in the head group results in an attraction with 
the nucleic acid that is so strong that the release of the nucleic acid is hindered which results in a 













Figure 2.5: Structure of cationic lipid Chol-T showing the four basic structural components 
 
 
 Figure 2.6: Structure of cationic lipid MSO9 showing the four basic structural components 
 
Head          Spacer arm        Linker                            Lipid anchor 




All six cationic liposomes were prepared with the neutral lipid DOPE (Figure 2.2). DOPE is 
usually incorporated into cationic liposome formulations as a helper lipid as most cationic lipids 
form micelles and not liposomes (Singh, 1998). DOPE is said to aid in membrane fusion as well 
as destabilization of the cellular and endosomal membrane as this neutral lipid has the ability to 
adopt the reverse hexagonal HII phase which is a non-bilayer phase (Dass and Choong, 2006; 
MacLachlan, 2007). Additionally, cationic liposome formulations are stabilized by the presence 
of DOPE as cationic liposomes repel each other. Liposomes formulated in the absence of DOPE 
are shown to have inferior rates of cell uptake and transfection (Dass and Choong, 2006). The 
addition of DOPE is also said to reduce the cytotoxicity of the cationic liposomes (Sternberg et 
al., 1994). 
 
The final constituent of the liposome preparations is DSPE-PEG2000. DSPE-PEG2000 was 
incorporated into the cationic liposomes at concentrations of 2 and 5 mole percentages. This was 
accomodated by reducing the percentage of DOPE in the respective liposomes. 
Distearoylphosphatidylethanolamine is present in the PEG molecule and serves as the lipid 
anchor which is attached to the PEG moiety via a carbamate linkage (Rejmana et al., 2004). PEG 
is a hydrophilic polymer, which, upon incorporation into the bilayer of the liposome, protrudes 
from the liposomal surface and affords a steric barrier to the liposome. In doing so, any 
interactions between the liposome and biological molecules are reduced, the liposome is 
stabilized and its circulation time in the blood is increased (Hong et al., 1997; Song et al., 2002). 
 
2.3.2  Transmission Electron Microscopy (TEM) 
 
Transmission electron microscopy of all six liposome preparations revealed the unilamellar 
nature of the liposomes (Figures 2.7 and 2.8). All the liposomes were spherical to oval in shape 
whilst some also exhibited a deformable nature. Artefacts present in some of the images can be 




                     
  (a)        (b) 
 
 
          (c) 
Figure 2.7: Transmission electron micrographs of (a) Chol-T, (b) 2% PEG2000Chol-T and (c) 





                 




Figure 2.8: Transmission electron micrographs of (a) MSO9, (b) 2% PEG2000MSO9 and (c) 




The average size measured for Chol-T was 120.7 nm, 2% PEG2000Chol-T was 37.85 nm and 5% 
PEG2000Chol-T was 43.67 nm (Figure 2.9). Measurements obtained for MSO9 and the pegylated 
(2 and 5 mole percent) MSO9 liposomes were 86.5 nm, 38.23 nm and 43.98 nm, respectively 
(Figure 2.10). It appears that the sizes of the liposomes are reduced upon pegylation. Lee et al. 
(2005) made a similar observation during their studies and attributed this to the incorporation of 
the PEG molecule onto the liposomal surface. They proposed that the PEG molecules present on 
the liposomal surface tend to repel each other, which prevents aggregation of the liposomes 
during preparation and hence, leads to the formation of smaller sized vesicles (Lee et al., 2005). 
Statistical analyses of liposome and lipoplex (Chapter 3) dimensions are presented as means ± 
SD. Results were examined by one way ANOVA and groups were compared by Student’s t-test. 




Figure 2.9: Average sizes of cationic liposome preparations Chol-T, 2% PEG2000Chol-T and 





Figure 2.10: Average sizes of cationic liposome preparations MSO9, 2% PEG2000MSO9 and 
5% PEG2000MSO9. Data presented as a means ± S.D (n = 5) (* p < 0.05). 
 
The size of the liposome plays a major part in their accumulation in the body and their blood 
clearance rates (Lee et al., 2005; Campbell et al., 2001). Although the size of the liposomes was 
determined using TEM in this study, additional information on the distribution of the liposome 
population may also be determined by dynamic light scattering and zeta sizing, the relevant 
instrumentation was not available at UKZN. However, cryo-electron microscopy with a brief and 
relatively mild negative staining affords images of liposome vesicles which may be sized reliably 

















Cationic liposomes are formulated with positively charged lipids that physically associate via 
charge interactions with negatively charged nucleic acids. These complexes that are formed are 
termed lipoplexes, a term that was coined by Felgner et al. (1997) to describe complexes formed 
between cationic liposomes and DNA, however, this term has now been broadened to describe 
the interaction between cationic liposomes and negatively charged nucleic acids (DNA and 
RNA) (Felgner et al., 1997; Thomas et al., 2009). A lipoplex, therefore, is composed of the 
cationic liposome containing a neutral helper lipid and the nucleic acid.  
 
Although much information is available to describe the physical structures of DNA lipoplexes, 
very little is known about the exact structure and properties of siRNA lipoplexes. Due to the 
presence of charge complementarities between the siRNA and the cationic liposomes, lipoplexes 
are spontaneously formed via electrostatic interactions between the positively charged head 
groups of the cationic liposomes and the negatively charged phosphate backbone of the siRNA 
(Ramon et al., 2008). The lipoplexes are prepared by simply mixing the nucleic acid and the 
cationic liposomes and incubating for a short period of time (Guo et al., 2010). It has been 
proposed that due to these charge interactions, the siRNA becomes physically associated with the 






Figure 3.1: Illustration of the physical association between the siRNA and cationic liposome 
(siRNA lipoplex) (Santel et al., 2006) 
 
The main forces involved in the spontaneous formation of lipoplexes include electrostatic forces 
and elastic forces, that is, the bending and stretching forces. When the lipoplexes are formed, the 
electrostatic forces are lowered due to the neutralization of the positive charges of the cationic 
liposome by the negatively charged nucleic acids, however, this must be higher than the elastic 
energy of the liposome, which results in the lipoplex geometry being achieved (Zuidom et al., 
1999). 
 
In this study, complexes were prepared with the non-pegylated and pegylated cationic liposomes 
and control, non targeting siRNA. The optimum binding ratios were determined from the gel 
retardation assay. This assay is based on the observation that lipoplexes do not migrate or 
migrate slower in an agarose gel as compared to the free nucleic acid. The assay is carried out by 
preparing lipoplexes and subjecting them to agarose gel electrophoresis. The gel is then analyzed 
to view any migration of the siRNA within the gel. The protection afforded by the cationic 






electrophoresis. The ultrastructural characteristics of the siRNA lipoplexes prepared were studied 
using transmission electron microscopy. 
 
3.2 MATERIALS AND METHOD 
3.2.1 Materials 
Control, non-targeting siRNA and 5× siRNA buffer was purchased from Thermo Scientific 
Dharmacon Products (Lafayette, CO, USA). Ultrapure Agarose was purchased from Invitrogen 
(Spain). Ethidium Bromide was obtained from Merck (Dermstadt, Germany). RNase A was 
purchased from Novagen, Calbiochem (USA). Ultrapure water (Milli-Q50) was utilized for all 
assays. All other reagents were of analytical grade. 
 
3.2.2 Method 
3.2.2.1 Resuspension of siRNA 
Control siRNA (20 pmoles) was resuspended using 1 ml of 1× RNA buffer, prepared from a 5× 
RNA buffer stock (Dharmacon, Lafeyette, CO, USA) with 18 MOhm water. The suspension was 
then vortexed and inverted to ensure that the siRNA was properly resuspended. The 
concentration of the stock was then determined using a Thermo Biomate 3 spectrophotometer 
and was found to be 0.29 g/l. 
 
3.2.2.2 Gel Retardation Assays 
 
A 2% (w/v) agarose gel was prepared by dissolving 0.4 g of agarose in 18 ml of 18 MOhm water 
(100 °C). Once all the agarose had dissolved, 2 ml of 10× electrophoresis buffer (0.36 M Tris 
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HCl, 0.3 M sodium phosphate, 0.1 M EDTA, pH 7.5) and 3 l of ethidium bromide was added to 
the gel to afford a final concentration of 1 g/ml. The gel was then allowed to set for an hour. 
Cationic liposome: siRNA complexes of varying ratios were prepared as seen in Tables 3.1 
(Chol-T), 3.2 (2%PEG2000 Chol-T), 3.3 (5%PEG2000Chol-T), 3.4 (MSO9), 3.5 (2%PEG2000-
MSO9) and 3.6 (5%PEG2000-MSO9). A constant concentration of siRNA (0.5 g) was added to 
increasing amounts of the cationic liposomes. These complexes were then made up to 10 l with 
HBS.  The reaction mixtures were incubated at room temperature for 30 minutes. Gel loading 
buffer (40% sucrose, 0.5% Bromophenol Blue, 2 l) was added to each reaction mixture 
following this incubation. The siRNA lipoplexes were then subjected to agarose gel 
electrophoresis for 30 minutes at 50 volts using a 2% agarose gel in a Bio-Rad electrophoresis 
tank which contained 1× electrophoresis buffer (36 mM Tris-HCl, 30 mM sodium phosphate, 10 
mM EDTA pH 7.5). Thereafter, the gel was viewed under UV transillumination at 300 
millisecond exposure time in a Vacutec Syngene G:Box gel documentation system.   
 
Table 3.1:  Chol-T cationic liposome: siRNA complexes 
siRNA lipoplexes 1 2 3 4 5 6 7 8 
siRNA (g) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Chol-T (g) - 2 3 4 5 6 7 8 
 
Table 3.2:  2% PEG2000Chol-T cationic liposome: siRNA complexes 
siRNA lipoplexes 1 2 3 4 5 6 7 8 
siRNA (g) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
2%PEG2000   
Chol-T (g) 




Table 3.3:  5% PEG2000Chol-T cationic liposome: siRNA complexes 
siRNA 
lipoplexes 
1 2 3 4 5 6 7 8 
siRNA (g) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
5%PEG2000 
Chol-T (g) 
- 4 5 6 7 8 9 10 
 
 
Table 3.4:  MSO9 cationic liposome: siRNA complexes 
siRNA 
lipoplexes 
1 2 3 4 5 6 7 8 
siRNA (g) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
MSO9 (g) - 3 4 5 6 7 8 9 
 
 
Table 3.5:  2% PEG2000 MSO9 cationic liposome: siRNA complexes 
siRNA 
lipoplexes 
1 2 3 4 5 6 7 8 
siRNA (g) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
2% PEG2000 
MSO9 (g) 




Table 3.6:  5% PEG2000 MSO9 cationic liposome: siRNA complexes 
siRNA 
lipoplexes 
1 2 3 4 5 6 7 8 
siRNA (g) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
5% PEG2000 
MSO9 (g) 
- 22.5 25 27.5 30 32.5 35 37.5 
 
 
3.2.2.3 Nuclease Protection Assays 
 
The siRNA lipoplex ratios used in this study are shown in Table 3.7 and represent the sub-
optimum, optimum and supra-optimum binding ratios as determined in the gel retardation assays. 
The complexes were prepared using a constant amount of control siRNA (0.3 µg) and made up 
to a final volume of 10 µl with HBS. Two controls were used for this study, namely, siRNA in 
the absence of the cationic liposome and RNase A (negative control) and siRNA in the presence 
of RNase A but in the absence of the cationic liposome (positive control). The freshly prepared 
lipoplexes were allowed to mature at room temperature for 30 minutes. Thereafter, RNase A     
(1 µg/µl) was added to the siRNA lipoplexes to a concentration of 0.1 g/l and the mixtures 
were then incubated for a further 2 hours at 37 ˚C. Following this incubation period, 
ethylenediaminetetraacetic acid (EDTA) and sodium dodecyl sulphate (SDS) were added to the 
reaction mixtures to a final concentration of 10 mM and 0.5%, respectively. This was followed 
by a further incubation at 55˚C for 20 minutes. Thereafter, the siRNA lipoplexes were subjected 
to agarose gel electrophoresis on a 2% agarose gel as in 3.2.2.2. The gel was then viewed and the 











Chol-T 1.8 2.4 3 
2% PEG2000-Chol-T 2.4 3 3.6 
5% PEG2000-Chol-T 3.6 4.2 4.8 
MSO9 3 3.6 4.2 
2%PEG2000-MSO9 13.2 13.8 14.4 
5%PEG2000-MSO9 9 12 15 
 
 
3.2.2.6  Transmission Electron Microscopy of siRNA: Cationic Liposome Complexes  
 
Lipoplexes were prepared using the ratios at which complete retardation of 0.5 g of control 
non-targeting siRNA was obtained. These complexes were allowed to incubate at room 
temperature for 30 minutes. The protocol outlined in section 2.2.2.2 for the transmission electron 






3.3 RESULTS AND DISCUSSION 
 
3.3.1   Gel Retardation Assay 
 
The results obtained from the gel retardation assay using the cationic liposomes formulated with  
either cytofectin Chol-T or MSO9 with different degrees of pegylation (0, 2 and 5 mole percent) 
can be seen in Figures 3.3 and 3.4. Each liposome shows different optimum binding ratios. These 
optimum binding ratios together with their corresponding charge ratios are shown in Table 3.8. 
The charge ratios were derived assuming that an average nucleotide molecular mass of 350 with 
one negative charge per nucleotide and a single positive charge per cytofectin molecule at pH 
7.5. 
 
Table 3.8: Optimum Binding Ratios and Charge Ratios of the cationic liposomes and 
pegylated cationic liposomes with siRNA 
LIPOSOME PREPARATION siRNA: Liposome ratio 
(w/w) 
Charge Ratio (-ve/+ve) 
Chol-T 1: 8 1: 1.9 
2% PEG2000-Chol-T 1: 10 1: 2.2 
5% PEG2000-Chol-T 1: 14 1: 2.8 
MSO9 1: 12 1: 2.5 
2% PEG2000-MSO9 1: 46 1: 8.6 
5% PEG2000-MSO9 *  







      
       (a)     (b)         (c)  
Figure 3.2: Gel Retardation analysis of binding interactions between varying amounts of 
cationic liposome preparations containing cytofectin Chol-T and 0-5% of DSPE-
PEG2000 with control siRNA (0.5 g) in a reaction volume of 10 l. 
  (a) Varying amounts of non-pegylated Chol-T in lanes 2-8 (2,3,4,5,6,7,8 g)  
           (b) Varying amounts of 2% PEG2000 Chol-T in lanes 2-8 (3,4,5,6,7,8,9 g) 
           (c) Varying amounts of 5% PEG2000 Chol-T in lanes 2-8 (4,5,6,7,8,9,10 g) 
           while control siRNA was kept constant at 0.5 g per well.  
* White arrows indicate end point ratios 
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       (a)                                                (b)                                                 (c) 
Figure 3.3: Gel Retardation analysis of binding interactions between varying amounts of 
cationic liposome preparations containing cytofectin MSO9 and 0-5% of DSPE-
PEG2000 with control siRNA (0.5 g) in a reaction volume of 10 l. 
  (a) Varying amounts of non-pegylated MSO9 in lanes 2-8 (3,4,5,6,7,8,9 g)  
           (b)       Varying amounts of 2% PEG2000 MSO9 in lanes 2-8 (18, 19, 20, 21, 22,  
                         23, 24 g). 
  
           (c) Varying amounts of 5% PEG2000 MSO9 in lanes 2-8 ( 22.5,25,27.5, 30,      
                                     32.5, 35, 37.5 g). 
 
            while control siRNA was kept constant at 0.5 g per well. 
 
*White arrows indicate endpoint ratios 






The gel retardation assay was carried out using a constant amount of non-targeting control 
siRNA (0.5 g) and increasing amounts of the various cationic liposome preparations. Agarose 
gel electrophoresis is used to show the complexation that occurs between the siRNA and the 
cationic liposome. In lane 1, siRNA was present in all gels in the absence of any cationic 
liposome. In this lane, the siRNA, which is anionic, migrates into the agarose gel towards the 
positively charged electrode and a bright, single band is present which is visible after ethidium 
bromide staining. The siRNA in this particular lane serves as a control and allows one to view 
the migration of naked siRNA in an agarose gel. With increasing amounts of cationic liposome, 
the siRNA becomes liposome bound via electrostatic interactions between the positive charges of 
the cationic liposome and the negative charges of the siRNA and is retained in the wells. At 
complete retardation, the cationic liposomes and siRNA form complexes which do not migrate 
through the small pores in the agarose gel during electrophoresis and remain in the wells. These 
complexes can be seen in the wells after ethidium bromide staining. In some cases, the 
electroneutral complexes may precipitate in the wells, which results in these complexes floating 
out of the wells (Singh, 1998). In these cases, the siRNA is not detected in the wells (Figure 3.3 
c). 
 
The 5% PEG2000 Chol-T liposome showed a higher liposome: siRNA binding ratio compared to 
the 2% PEG2000 Chol-T and the Chol-T liposomes. Complete retardation of 0.5 g of siRNA was 
obtained using 4 g of Chol-T (Figure 3.2 a), 5 g of 2% PEG2000 Chol-T (Figure 3.2 b) and 7 g 
of 5% PEG2000 Chol-T (Figure 3.2 c). As the concentration of each liposome increased, their 
binding to the siRNA also increased. These results suggest that with an increase in the degree of 
liposome pegylation, the ratio to obtain complete retardation of the siRNA also increases. A 
similar result was obtained by Zhang and co-workers (2010) who found that an increase in 
pegylation had weakened the binding affinity of the siRNA with the cationic liposome being 
studied, namely, DC-Chol/ DOPE liposome and therefore, the binding ratios to achieve complete 




The same pattern was observed with the cationic liposomes formulated with the cytofectin 
MSO9 and different degrees of pegylation. Complete retardation of 0.5 g siRNA was achieved 
with 6 g of MSO9 (Figure 3.3 a) and 23 g of 2% PEG2000 MSO9 (Figure 3.3 b).  The 5% 
PEG2000 MSO9 was not able to fully complex the siRNA at a ratio of 1:75 (37.5 g of the 
liposome). Therefore, three ratios, namely, 1:30, 1:40 and 1:50, were selected for further studies.  
 
From the gel retardation studies it is observed that an increase in the degree of pegylation 
increases the charge ratio at the end point (Table 3.8). This could be attributed to the presence of 
the PEG molecule on the liposomal surface. During the formulation of the liposomes, the 
introduction of PEG may have resulted in the internalization of the cytofectin (Chol-T and 
MSO9) hence, the amount of positive charge available for interaction with the negatively 
charged siRNA is reduced. Furthermore, the presence of PEG may have a shielding effect on the 
positive charges afforded by the cytofectins, and, therefore, the interaction of the cationic 
liposome with the siRNA will be affected.  
 
The results obtained for the gel retardation assay have been used in the design of transfection 
complexes for the transfection studies in the Hela tat luc cells in culture, which is described in 
chapter four. Hence, the sub-optimum, optimum and super optimum siRNA: liposome ratios 









3.3.2  Nuclease Protection Studies 
One of the obstacles in inducing RNAi with the introduction of siRNA is the susceptibility of the 
siRNA to nucleases in the blood serum, such as RNase, during circulation and in the interstitial 
space (Lu et al., 2009). A desirable feature of any delivery vector is their ability to protect the 
siRNA from degradation by nucleases.  
The ability of the six liposomes prepared to protect the siRNA from enzymatic degradation was 
studied using the nuclease protection assay. The results obtained are presented in Figure 3.4 and 
3.5. 
         
     (a)         (b)     
Figure 3.4:  Nuclease Protection Assay using varying amounts of pegylated and non-pegylated 
Chol-T cationic liposome in a 10 l reaction mixture with 0.3 g of non-targeting 
siRNA. 
  Lane 1: undigested siRNA (0.3 g) 
  Lane 2: unprotected siRNA (0.3 g) digested by 10% RNase A. 
   
  (a) Lanes 3-5: Varying amounts of Chol-T (1.8, 2.4, 3 g) with siRNA and 10%                                                     
RNase A. 
   Lanes 6-8: Varying amounts of 2% PEG2000 Chol-T (2.4, 3, 3.6 g) with 
siRNA and 10% RNase A. 
  (b)Lanes 3-5: Varying amounts of 5% PEG2000 Chol-T (3.6, 4.2, 4.8 g) with 
siRNA and 10% RNase A.  
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     (a)               (b) 
Figure 3.5: Nuclease Protection Assay using varying amounts of pegylated and non-pegylated 
MSO9 cationic liposome in a 10 l reaction mixture with 0.3 g of non-targeting 
siRNA. 
  Lane 1: undigested siRNA (0.3 g) 
  Lane 2: unprotected siRNA (0.3 g) digested by 10% RNase A. 
   
  (a) Lanes 3-5: Varying amounts of MSO9 (3, 3.6, 4.2 g) with siRNA and 10%                                                     
RNase A. 
  (b)Lanes 3-5: Varying amounts of 2% PEG2000 MSO9 (13.2, 13.8, 14.4 g) with 
siRNA and 10% RNase A. 
       Lanes 6-8: Varying amounts of 5% PEG2000 MS09 (9, 12, 15 g) with siRNA 
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EDTA is added to the complexes to stop the action of the enzyme RNase A. Sodium dodecyl 
sulphate (SDS) is used to release the bound siRNA from the siRNA- liposome complex. These 
complexes are then subjected to agarose gel electrophoresis where the unbound, negatively 
charged siRNA will migrate into the gel during electrophoresis. 
 
The cationic liposome: siRNA ratios used for this study were those obtained from the gel 
retardation assay. The liposome bound siRNA appears to be protected from nuclease degradation 
at the three ratios used, and not just at the optimum binding ratio. The results obtained suggest 
that the non-pegylated and pegylated Chol-T liposomes afford protection of the siRNA in the 
siRNA lipoplex. This can be deduced when comparing the results obtained in lane 2 (Figures 3.4 
a-c) to those achieved by the lipoplexes. The unprotected siRNA in lane 2 was completely 
degraded in the presence of 0.1 g/l RNase A whereas the siRNA released from the siRNA 
lipoplexes is intact and migrates as a single band in the gel during electrophoresis. A similar 
result was seen with the MSO9 and the 2% PEG2000MSO9 where protection of the siRNA was 
evident following electrophoresis. It has been suggested in studies with DNA that the 
electrostatic interaction between the negatively charged DNA and the cationic liposomes results 
in the formation of highly organized structures where the DNA molecules are condensed and 
protected against enzymatic degradation (Singh, 2005). Since a similar electrostatic interaction 
occurs between the cationic liposomes and the polyanionic siRNA molecule, it can be suggested, 
that a similar condensed lipoplex could be formed and, therefore, the siRNA was protected 
against RNase A degradation.   
 
The siRNA band intensities in lanes 6-8 in Figure 3.5 (b) suggest that the 5% PEG2000MSO9 
liposome afforded less protection to the siRNA than the MSO9 (Figure 3.5 a) and the 2% 
PEG2000MSO9 preparations (Figure 3.5 (b) lanes 3-5). In this regard it is noteworthy that the gel 
retardation analysis for the 5% PEG2000MSO9 did not reveal an end point, that is, an optimum 
binding ratio. Hence, it can be assumed that not all the siRNA was liposome bound and 
therefore, a proportion of siRNA was exposed to enzymatic degradation by RNase A. Partial 
siRNA protection was also obtained by Kim et al. (2010) whose liposomes had shown partial 
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protection of the siRNA. They attributed their results to the process of the interaction between 
the siRNA and the cationic liposome which may result in the incomplete complexation of the 
siRNA molecules, and, therefore, the siRNA is exposed to potential degradation by the enzymes. 
 
The protection afforded to the siRNA by the liposomes is promising for transfection studies in 
vitro and in vivo, as this increases the delivery of large amounts of intact siRNA to the target 
cells, which is required for efficient gene knockdown. 
 
 
3.3.3  Transmission Electron Microscopy of siRNA Lipoplexes 
 
Cryo-TEM was used to determine the ultrastructural characteristics and sizes of the different 
siRNA lipoplexes being utilized in this study. The siRNA lipoplexes were prepared using the 
ratios at which optimal binding was achieved. 
 
The cryo-TEM images revealed siRNA lipoplexes that appeared as spherical clusters, some of 
which also appeared to have a deformable nature (Figure 3.6 a-c and Figure 3.7 a-c). The sizes of 
the siRNA lipoplexes were also measured and are represented in Figures 3.8 and 3.9. The 








                                                     




            (c) 
 
Figure 3.6: Transmission electron micrographs of (a) siRNA:Chol-T lipoplex,                      
(b) siRNA: 2% PEG2000Chol-T lipoplex and (c) siRNA: 5% PEG2000Chol-T 




                         




            (c) 
Figure 3.7: Transmission electron micrographs of (a) siRNA: MSO9 lipoplex,                      
(b) siRNA: 2% PEG2000MSO9 lipoplex and (c) siRNA: 5% PEG2000MSO9 





It has been reported that the sizes of lipoplexes are said to range between 50 nm to 200 nm in 
diameter (Thomas et al., 2007). The images obtained following cryo-TEM are consistent with 
the above as the sizes of the lipoplexes were within this range. Chol-T lipoplexes had a mean 
diameter of 140.2 nm and 2% PEG2000 Chol-T lipoplexes and 5% PEG2000 Chol-T lipoplexes 
exhibited mean diameters of 134 nm and 87.65 nm, respectively. The average sizes of MSO9, 
2% PEG2000 MSO9 and 5% PEG2000 MSO9 lipoplexes were 153 nm, 100 nm and 128.6 nm, 
respectively. The results obtained indicate that the sizes of the lipoplexes are much larger than 
the corresponding liposomes and pegylation appears to reduce the sizes of the lipoplexes. These 
results are consistent with those obtained by Zhang et al (2010) who suggested that a large 
lipoplex may form during neutralization of the lipoplex charge and they also found that 




Figure 3.8: Average sizes of siRNA: Chol-T lipoplexes, siRNA: 2% PEG2000Chol-T 
lipoplexes and siRNA: 5% PEG2000Chol-T lipoplexes at optimum binding ratios. 







Figure 3.9:  Average sizes of siRNA: MSO9 lipoplexes, siRNA: 2% PEG2000MSO9 lipoplexes 
and siRNA: 5% PEG2000MSO9 lipoplexes at optimum binding ratios. 0.5 g of 
siRNA is present.  Data presented as a means ± S.D (n = 5) (* p < 0.05) 
 
The large standard deviations (n > 10%) suggests that there are variations that exist in the sizes 
of the lipoplex population and these variations in size could affect the transfection of the 
liposomes, however, there are conflicting reports that have been published on the relationship 
between lipoplex size and in vitro transfection efficiency. The trend is clearer for in vivo 
conditions as lipoplexes have to be small enough (generally < 150 nm) to extravasate in order to 
reach the target organs (Singh, 2005). 
 
 
                           
                               
 










The delivery of a target gene into the appropriate cell is termed transfection and can be regarded 
as a powerful tool in cell biology (Weber et al., 1995). More recently, there have been many 
advances in this field to enhance transfection by improving on the methods whereby a gene of 
interest is introduced into an appropriate cell. 
 
RNA interference (RNAi) is regarded as one of the major discoveries in biology in recent years 
(Shan, 2009). RNAi, in mammalian cells, can be initiated by the introduction of short (21-23 
nucleotides) synthetic RNA duplexes. These siRNA sequences are capable of inhibiting 
translation of the cognate mRNA sequence, which occurs in a sequence specific manner, and 
hence, the production of the corresponding protein is inhibited (Thomas et al., 2009). 
Theoretically, a sequence of siRNA can be designed to target any given mRNA, a process which 
can be exploited for therapeutic use (Shan, 2009; Thomas et al., 2009). An example of such a 
methodology involves the design of a siRNA molecule which can be used to target K-RAS 
transcripts that carry a valine-112 (K-RASV112) mutation. This is an oncogene mutation that 
activates the RAS gene which, in turn, leads to pancreatic and colon cancer. Knockdown of this 
K-RASV112 gene may result in the degradation of the K-RASV112 gene which can delay the onset 
of the disease (Ryther et al.,2005).  A similar principle was applied in this study, with the gene of 
interest being luciferase and the efficiency of transfection of the cationic liposomes was 
determined by knockdown of the luciferase gene in the HeLa tat luc cell line, a cell line that 
stably expresses the luciferase gene. 
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The HeLa cell line is an immortal cell line isolated from a human cervical carcinoma and is one 
of the most popular culture cells used for biological studies (Starr and Taggart, 2004). The HeLa 
cells utilized in this study, as mentioned previously, stably express the Firefly luciferase gene. 
Luciferase is one of the most studied enzymes in both DNA and RNA studies and can catalyze 
light production in bioluminescent organisms (Singh, 1998). The substrates that are required for 
the action of luciferase include luciferin, ATP and oxygen (Singh, 2005). The Firefly luciferin 







Figure 4.1: Structure of Firefly D-(-)-Luciferin (Narainpersad, 2009) 
 
 
In this study, an attempt was made to develop synthetic cationic liposome based gene transfer 
systems that could be used for the successful delivery of siRNA. These cationic liposomes were 
enhanced by pegylation in an attempt to improve the circulation time of the cationic liposomes. 
Pegylation was achieved by introducing DSPE-PEG2000 into the liposomal formulation. 
Lipoplexes were prepared with the cationic liposomes together with the anti-luciferase siRNA 
and a reduction in the luciferase activity (gene knockdown) in the HeLa tat luc cells after 














4.2 MATERIALS AND METHOD 
4.2.1 MATERIALS 
 
HeLa tat luc cell line was provided by the Department of Physiology, University of KwaZulu- 
Natal, Westville Campus. Anti- luciferase siRNA was purchased from Thermo Scientific 
Dharmacon Products (Lafayette, CO, USA). Minimal Essential Medium (MEM) and foetal calf 
serum (FCS) was purchased from GIBCO, Life Technologies Ltd (Inchinnan, Scotland). 
Trypsin-EDTA and penicillin-streptomycin mixtures were purchased from Lonza BioWhittaker 
(Walkersville, USA).  All tissue culture plastic wear was purchased from Corning Incorporated 
(New York, USA). The Luciferase Assay Kit (Luciferase Assay reagent and Cell Culture Lysis 
reagent) was purchased from Promega Corporation (Madison, USA). The Bicinchoninic acid 
(BCA) assay reagents were purchased from Sigma-Aldrich Co (St. Louis, USA). 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) salt was purchased from Merck 
(Darmstadt, Germany). All other reagents were of analytical grade. 
 
4.2.2 METHOD 
4.2.2.1 Growth and Maintenance of HeLa tat luc Cell Line 
 
4.2.2.1.1 Reconstitution of HeLa tat luc Cells 
 
The HeLa tat luc cells which were cryopreserved were obtained in an ampoule and were 
immediately placed in a 37°C water bath to thaw. The cell suspension was then transferred, 
aseptically, to a centrifuge tube and centrifuged at 1000 rpm for 5 minutes using a MSE bench 
top centrifuge. This resulted in a pellet of cells. The supernatant was then discarded and the 
pellet of cells were resuspended with 1 ml of complete medium (MEM + 1% Antibiotic + 10% 
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FCS). The cell suspension was then transferred to a 25 cm3 tissue culture flask containing 4 ml of 
complete medium. The flask was then placed in a 37°C incubator and checked regularly.  
 
4.2.2.1.2 Propagation of HeLa tat luc Cell line 
 
Once the cells had reached confluency or semi-confluency, they were trypsinized. This was done 
by discarding the growth medium and washing the cells with 5 ml of phosphate buffered saline 
(PBS) (150 mM NaCl, 2.7 mM KCl, 1 mM KH2PO4, 6 mM Na2HPO4; pH 7.5). The PBS was 
then decanted and 1ml of trypsin-EDTA was then added to the cells for trypsinization. A Nikon 
TMS inverted microscope was used to observe the trypsinization of the cells. The trypsinization 
time for the HeLa tat luc cells was approximately 2 minutes. Once the cells had rounded off,      
2 ml of complete medium was added to the cells and the flask was tapped gently on the palm of 
the hand. The cells were then split to a desired ratio into 25 cm2 tissue culture flasks or multiwell 
plates as required. Each flask contained 5ml of complete medium and the cells were incubated at 
37°C. The cells were checked at regular intervals and the medium was changed when necessary. 
Once the cells had reached confluency, they were trypsinized again and split to required ratios or 
they were frozen and stored at -80°C in a NUAIRE biofreezer (4.2.2.1.3). 
 
4.2.2.1.3 Cryopreservation of HeLa tat luc Cells 
 
Cells that had reached confluency were washed with PBS and trypsinized following the 
procedure outlined in section 4.2.2.1.2. Thereafter, the cells were pelleted by centrifugation using 
a MSE bench top centrifuge for 3 minutes at 1000 rpm. The medium was decanted and 0.9 ml of 
complete medium and 0.1 ml of dimethylsulphoxide (DMSO) was added to the pelleted cells 
which were then resuspended. The cells were then transferred to a cryogenic ampoule and frozen 
using one of two methods. The first method involves the use of a cold probe. Here the cells were 
frozen to -70°C at a drop rate of 1°C per minute from room temperature. The cells were then 
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stored at -80°C in a NUAIRE biofreezer. In the second method, the cryogenic ampoule was 
transferred to a NALGENE Cryo 1°C Freezing Container which contains isopropanol. This 
freezing container is placed directly into the NUAIRE biofreezer at -80°C. The ampoules were 
then removed from the container after 4 hours and stored in the biofreezer at -80°C.  
 
 4.2.2.2  siRNA duplexes 
 
SiGENOME non-targeting siRNA (D-001210-01) and Anti-Luc siRNA-1 (D-002050-01) were 
obtained from Thermo Scientific Dharmacon Products (Lafayette CO). The anti-luciferase 
siRNA is specific for the firefly luciferase gene and HeLa tat luc cells that are successfully 
transfected with the anti-luciferase siRNA lipoplexes will exhibit a decrease in luciferase 
expression. The target sequence of the anti-luciferase siRNA is 5’-GAU UAU GUC CGG UUA 
UGU A(UU)-3’.  The non-targeting siRNA duplex contains at least four mismatches with all 
known human genes and is used in the transfection studies to assess non-sequence specific 
effects of the siRNA lipoplexes on the HeLa tat luc cells in vitro. The target sequence of this 
siRNA duplex is 5’-UAG CGA CUA AAC ACA UCA A-3’.  The siRNA duplexes were 
resuspended as outlined in section 3.2.2.1.  
 
4.2.2.3 Cytotoxicity Studies 
 
The HeLa tat luc cells were trypsinized and seeded into 48 well plates at different seeding 
densities. For the toxicity studies using Chol-T, 2% PEG2000Chol-T and 5% PEG2000Chol-T, the 
cells were seeded at 2.2×104 cells per well and for the MSO9, 2% PEG2000-MSO9 and 5% 
PEG2000-MSO9 cationic liposomes the cells were seeded at 2.1×104 cells per well. The cells were 
incubated at 37°C and allowed to attach overnight. The siRNA lipoplexes were prepared as in 
table 4.1. Three concentrations of anti-luciferase siRNA were used, namely, 20 nM (0.067 g), 
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30 nM (0.1 g) and 50 nM (0.17 g). All the complexes were made up to a final volume of 10 l 
with HBS and incubated at room temperature for 30 minutes. 
 
Once the reaction mixtures were prepared, the growth medium was removed and replaced with 
0.25 ml of serum free medium (MEM + 1% Antibiotics). The complexes were then added to the 
wells containing the cells. All the assays were done in triplicate. The multiwell plates were then 
incubated at 37°C for 4 hours. Thereafter, the serum free medium was removed and replaced 
with 0.25 ml of complete medium. The cells were then incubated at 37 °C for 36 hours. After 
this time, the growth medium was removed and replaced with 0.2 ml of MTT (5 mg/ml in PBS) 
and 0.2 ml of complete medium. The cells were then incubated at 37°C for four hours. 
Thereafter, the MTT and the medium were removed and replaced with 0.2 ml of 
dimethylsulphoxide (DMSO). The absorbances were then measured at 540 nm using a Vacutec 
MR-96A microplate reader.   
 
Table 4.1:  siRNA: cationic liposome ratios used for cytotoxicity studies and transfection studies   
LIPOSOME PREPARATION siRNA: CATIONIC LIPOSOME RATIOS (w/w) 
CHOL-T 1:6 1:8 1:10 
2% PEG2000CHOL-T 1:8 1:10 1:12 
5% PEG2000CHOL-T 1:12 1:14 1:16 
MSO9 1:10 1:12 1:14 
2% PEG2000MSO9 1:44 1:46 1:48 





4.2.2.4 Transfection Studies 
 
4.2.2.4.1 Transfection Studies with Positive Control (Anti-Luciferase siRNA)  
 
The HeLa tat luc cells were seeded in 48 well plates at a cell density of 2.0×104 cells per well. 
The cells were incubated at 37°C overnight to allow for the attachment of the cells. The reaction 
mixtures of the siRNA and cationic liposomes were prepared according to the ratios in table 4.1 
and as outlined in section 4.2.2.3. The cells were prepared by removing the growth medium and 
replacing it with 0.25 ml serum free medium. The complexes were then introduced to the cells, 
each assay being done in triplicate. For this study, two controls were present. The first being the 
HeLa tat luc cells only and the second being the cells with naked anti-luciferase siRNA. All 
three concentrations of the anti-luciferase siRNA were studied. The 48 well plates were then 
incubated at 37°C for 4 hours. After this time, the medium was removed and replaced with 
complete medium. The multiwell plates were then incubated at 37°C for 36 hours. After this 
incubation, the luciferase activity of the cells was determined.    
 
4.2.2.4.2 Luciferase Assay 
 
The luciferase assay was carried out using the Promega Luciferase Assay kit. The cell culture 
lysis reagent (5x) (25 mM Tris-phosphate, pH 7.8; 2 mM dithiothreiotol, 2 mM 1,2-
diaminocyclohexane – N, N, N’N’- tetra-acetic acid, 10% (v/v) glycerol, 1% (v/v) triton X-100), 
was diluted to a 1× stock with distilled water. The luciferase assay reagent and the 1× cell culture 
lysis reagent were allowed to equilibrate to room temperature. 
 
The cells were prepared by removing the growth medium and washing twice with PBS. Eighty l 
of 1× cell culture lysis reagent was added to the cells. The multiwell plates were then placed on a 
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Stuart Scientific Platform Rocker for 15 minutes at 30 rev/ min. Thereafter, the lysed cells were 
dislodged from the multiwell plates by scraping the wells. The cell suspension was then 
transferred to microcentrifuge tubes and pelleted by centrifugation at 12000 × g for 20 seconds in 
an Eppendorf Microcentrifuge. The supernatant, being the cell free extract, was then retained for 
the determination of luciferase activity. This was done by adding 100 l of the luciferase reagent 
to 20 l of the cell free extract at room temperature. This was immediately mixed and placed in a 
Lumac Biocounter 1500 luminometer. The light produced was then measured for a period of 10 
seconds. The protein determination of the cell free extracts was then carried out using the BCA 
assay.  
 
4.2.2.4.3 Transfection Studies with Negative Control (Non- targeting Control siRNA) 
 
HeLa tat luc cells were seeded at a cell density of 1.8×104 cells per well in 48 well plates. The 
cells were allowed to attach overnight at 37°C. The complexes were prepared as outlined in 
section 4.2.2.3 as per Table 4.1. In this study, the non-targeting control siRNA was used when 
preparing the siRNA lipoplexes at the three concentrations, namely 20 nM, 30 nM and 50 nM. 
The same protocol was followed as outlined in section 4.2.2.4.1. The luciferase activity was 
determined as outlined in section 4.2.2.4.2. The protein determination of the cell free extracts 
was carried out using the BCA assay.    
 
4.2.2.5  Statistical Analysis 
 
Cell numbers and percentage of luciferase expression are presented as means ± SD. Results were 
examined by one way ANOVA and groups were compared by Student’s t-test. P values less than 




4.3 RESULTS AND DISCUSSION 
 
4.3.1 Growth and Maintenance of HeLa tat luc cells 
 
The HeLa tat luc cell line was grown and maintained in MEM + 1% Antibiotics + 10% New 
Born Calf Serum. Rapid cell growth was observed with the HeLa tat luc cells, which is a 
characteristic of this cell line. Confluency of the HeLa tat luc cells was reached within 3 to 4 
days. The HeLa tat luc cells were trypsinized upon reaching confluency and subdivided into 





Figure 4.2: Monolayer of HeLa tat luc cells at semi- confluency viewed under an Olympus 




4.3.2 Cytotoxicity Studies 
 
An ideal characteristic of non-viral vectors is safety and minimal toxicity, therefore, cell toxicity 
studies of the delivery vehicle, which is sometimes overlooked, is very important. It has been 
suggested that cationic lipids may have a toxic effect to cells in vitro. The toxicity of the cationic 
liposomes is due to the presence of the positive charges on the head group of the liposome (Lv et  
al., 2006). The cationic liposomes may interact with biological components that may induce 
aggregation or the germicidal action of the positive surfactants against bacteria, fungi, viruses 
and invertebrates (Lasic, 1997). 
 
In this study, the MTT cell proliferation assay was used to determine the toxicity of the cationic 
liposomes. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) is a yellow 
tetrazolium salt which is water soluble and is converted to an insoluble formazon product 
(Fotakis et al., 2006). This conversion is carried out by the mitochondrial enzyme, succinate 
dehydrogenase, which cleaves the tetrazolium ring. This reduction will only take place when the 
enzymes are active and, therefore, can be directly related to cell viability (Vellanen et al., 2004). 
Following solubilization of the formazon crystals by the addition of the solubilization agent, 
which was dimethylsulphoxide (DMSO), the absorbance of the resulting purple solution was 
then determined.  
 
All six lipoplex preparations were well tolerated by the HeLa tat luc cell line over the three 
different siRNA concentrations (20 nM, 30 nM and 50 nM). The control for this study was the 
untreated cells. Since these cells were not exposed to any siRNA lipoplexes, their absorbance 
readings were represented as 100% cell survival. The results for the cytotoxicity studies are 
























Figure 4.3 (c) 
 
Figure 4.3: Cytotoxicity of cationic liposome: siRNA complexes in HeLa tat luc cells in             
vitro. siRNA concentrations utilized were 20 nM (0.067 g), 30 nM (0.1 g) 
and 50 nM (0.168 g), 
   (a)  Varying concentrations of Chol-T (0.4 g, 0.54 g, 0.67 g/ 10 l),      
(0.6 g, 0.8 g, 1 g/10 l), (1.01 g, 1.34 g, 1.68 g/10 l) for the        
20 nM, 30 nM and 50 nM concentrations, respectively,                                            
  (b) Varying concentrations of 2% PEG2000Chol-T (0.54 g, 0.67 g, 0.8 g/ 
10 l), (0.8 g, 1 g, 1.2 g/10 l), (1.34 g, 1.68 g, 2.02 g/10 l) for 
the 20 nM, 30 nM and 50 nM concentrations, respectively, 
  (c) Varying concentrations of 5% PEG2000Chol-T (0.8 g, 0.94 g, 1.07 g/ 
10 l), (1.2 g, 1.4 g, 1.6 g/10 l), (2.02 g, 2.35 g, 2.69 g/10 l) for 
the 20 nM, 30 nM and 50 nM concentrations, respectively, 
   in a total volume of 0.25 ml medium (MEM). A control sample (no liposome), 
  contained only HeLa tat luc cells was assumed to have 100% survival. Data  


























Figure 4.4 (c) 
 
Figure 4.4: Cytotoxicity of cationic liposome: siRNA complexes in HeLa tat luc cells in 
vitro. siRNA concentrations utilized were 20 nM (0.067 g), 30 nM (0.1 g) 
and 50 nM (0.168 g). 
  (a) Varying concentrations of MSO9 (0.67 g, 0.8 g, 0.94 g/10 l), (1 g, 
1.2 g, 1.4g/10l), (1.68 g, 2.02 g, 2.4 g/10 l) for the 20 nM, 30 nM 
and 50 nM concentrations, respectively, 
  (b) Varying concentrations of 2% PEG2000MSO9 (2.95 g, 3.08 g, 3.22 
g/10 l), (4.4 g, 4.6 g, 4.8g/10 l), (7.4 g, 7.7 g, 8.06 g/10 l) for 
the 20 nM, 30 nM and 50 nM concentrations, respectively, 
  (c) Varying concentrations of 5% PEG2000MSO9 (2 g, 2.68 g, 3.35 g/10 
l), (3 g, 4 g, 5 g/10 l), (5.04 g, 6.72 g, 8.4 g/10 l) for the         
20 nM, 30 nM and 50 nM concentrations, respectively,  
  in a total volume of 0.25 ml medium (MEM). A control sample (no liposome), 
  contained only HeLa tat luc cells was assumed to have 100% survival. Data  








Maximum cell death recorded for the Chol-T lipoplexes was 25% at the 50 nM siRNA 
concentration, 37% for 2% PEG2000Chol-T and 39% for 5% PEG2000Chol-T at the 50 nM and 30 
nM siRNA concentrations, respectively (Figure 4.3 a-c). Cells treated with MSO9 showed 
maximal cell growth inhibition of 33% at the 50 nM siRNA concentration, and those cells 
exposed to 2% PEG2000MSO9 and 5% PEG2000MSO9 showed maximum cell death of 36% and 
33% at the 50 nM and 30 nM siRNA concentrations, respectively (Figure 4.4 a-c). 
 
The results obtained suggest that the pegylated cationic liposomes exhibit a marginally higher 
cytotoxicity levels as compared to the non-pegylated counterparts. This is consistent with the 
results obtained by Dadashzadeh et al. (2008), who showed that their pegylated cationic 
liposomes had a higher toxicity when compared to the non-pegylated cationic liposome.  
 
Another observation from the results is that for most of the liposomes, maximum growth 
inhibition of the cells occurred at the siRNA concentration of 50 nM. This could be attributed to 
the presence of a higher concentration of the cationic liposome that was exposed to the cells. 
This higher cationic liposome concentration was required since a higher siRNA concentration 
was used and the optimum binding ratios for each liposome was studied. A similar result was 
obtained by Zhang et al. (2010), who attributed an increase in the cytotoxicity of their liposomes 
to the presence of an increased amount of the cationic liposome being present. 
    
Overall, the relatively low toxicity of these lipoplexes is significant for their further development 







4.3.3    Transfection Studies  
 
The HeLa tat luc cell line was utilized for this study. This cell line is a human cervical cancer 
cell line which stably expresses the firefly luciferase gene. The anti- luciferase siRNA, which is 
specific for the firefly luciferase gene, was used to determine the efficiency of transfection of the 
cationic liposomes as a measure of gene knockdown. The results are presented in Figures 4.5 (a-
c) and 4.6 (a-c). 
  
Figure 4.5 (a) 
 
 











Figure 4.5 (c) 
 
Figure 4.5: Transfection studies of cationic liposome: anti-luciferase siRNA complexes in 
HeLa tat luc cells in vitro. siRNA concentrations utilized were 20 nM, 30 nM 
and 50 nM. 
  (a) Varying concentrations of Chol-T (0.4 g, 0.54 g, 0.67 g/10 l), (0.6 
g, 0.8 g, 1 g/10 l), (1.01 g, 1.34 g, 1.68 g/10 l) for the 20 nM,    
30 nM and 50 nM concentration, respectively, 
  (b) Varying concentrations of 2% PEG2000Chol –T (0.54 g, 0.67 g, 0.8 
g/10 l), (0.8 g, 1 g, 1.2 g/10 l), (1.34 g, 1.68 g, 2.02 g/10 l) 
for the 20 nM, 30 nM and 50 nM concentration, respectively,  
  (c) Varying concentrations of 5% PEG2000Chol -T (0.8 g, 0.94 g, 1.07 
g/10l), (1.2 g, 1.4 g, 1.6 g/10 l), (2.02 g, 2.35 g, 2.69 g/10 l) 
for the 20 nM, 30 nM and 50 nM concentration, respectively, 
   in a total volume of 0.25 ml medium (MEM). Control 1 contained HeLa tat luc 
cells only and Control 2 contained HeLa tat luc cells and siRNA only. Data 




























Figure 4.6 (c) 
 
Figure 4.6: Transfection studies of cationic liposome: anti-luciferase siRNA complexes in 
HeLa tat luc cells in vitro. siRNA concentrations utilized were 20 nM, 30 nM 
and 50 nM. 
 (a) Varying concentrations of MSO9 (0.67 g, 0.8 g, 0.94 g/10 l), (1 g, 
1.2 g, 1.4g/10 l), (1.68 g, 2.02 g, 2.4 g/10 l) for the 20 nM,        
30 nM and 50 nM concentrations, respectively, 
 (b) Varying concentrations of 2% PEG2000 MSO9 (2.95 g, 3.08 g, 3.22 
g/10 l), (4.4 g, 4.6 g, 4.8g/10 l), (7.4 g, 7.7 g, 8.06 g/10 l) for 
the 20 nM, 30 nM and 50 nM concentrations, respectively, 
 (c) Varying concentrations of 5% PEG2000 MSO9 (2 g, 2.68 g, 3.35 g/10 
l), (3 g, 4 g, 5 g/10 l), (5.04 g, 6.72 g, 8.4 g/10 l) for the        
20 nM, 30 nM and 50 nM concentrations, respectively, 
  in a total volume of 0.25 ml medium (MEM). Control 1 contained HeLa tat luc  
 cells only and Control 2 contained HeLa tat luc cells and siRNA only. Data  






The luciferase activity was measured as relative light units/mg protein (RLU/mg protein) and 
expressed as a percentage relative to a control (Control 1). Hence, in this assay, control 1 
represents untreated HeLa tat luc cells and, therefore, the RLU/mg protein was expressed as a 
100% as one could assume that the luciferase expression would be the highest in this control. 
  
A second control (Control 2) for this study represents cells that were treated with anti-luciferase 
siRNA only. Here, at all three siRNA concentrations used (20 nM, 30 nM and 50 nM), little gene 
knockdown was evident. When comparing all three siRNA concentrations, the maximum gene 
knockdown evident was 47.3% at 50 nM siRNA concentration. The siRNA, in this case, may 
have been taken up into the cell by processes that were not intended during the transfection 
experimient carried out. An example of such a mechanism can involve the attachment of the 
siRNA to lipoproteins on the cell surface. This may result in the cellular uptake of the siRNA 
which, in turn, can result in marginal gene knockdown. 
 
The results obtained with the cells treated with the cationic liposomes Chol-T and MSO9 showed 
efficient knockdown of the luciferase gene when compared to the controls (Figure 4.5 a-c and 
Figure 4.6 a-c). The results show that there was a significant difference in the luciferase 
expression of the control cells and those cells that were treated with the anti-luciferase siRNA 
lipoplexes (p < 0.05). Cells treated with Chol-T showed maximum gene knockdown at 30 nM 
siRNA concentration of 93.4% at a siRNA: Chol-T ratio of 1:6 and charge ratio of 1:1.3 (-/+) 
(Figure 4.5 a). The 2% PEG2000 Chol-T presented a maximum gene knockdown at a siRNA 
concentration of 50 nM of 75% at a siRNA : liposome ratio of 1:10 [charge ratio 1:2.2 (-/+)] 
(Figure 4.5 b) and 5% PEG2000  Chol-T was capable of 77.8% gene knockdown at the 20 nM 
siRNA concentration at a siRNA: liposome ratio of 1:16 [charge ratio of 1:3.1 (-/+)] (Figure 4.5 
c). 
 
The cells transfected with the MSO9 liposomes exhibited maximum gene knockdown of 84% at 
the siRNA concentration of 50 nM. This occurred at a siRNA: MSO9 ratio of 1:12 at a charge 
84 
 
ratio of 1:2.5 (-/+) (Figure 4.6 a). Maximum gene knockdown of 81.6% and 79.4% was evident 
for 2% PEG2000 MSO9 (Figure 4.6 b) and 5% PEG2000 MSO9 (Figure 4.6 c), respectively. This 
gene knockdown occurred at siRNA: liposome ratios of 1:46 (charge ratio of 1:8.6 (-/+)) and 
1:40 (charge ratio of 1:7.2 (-/+)) for the 2% PEG2000 MSO9 and 5% PEG2000 MSO9, 
respectively.  
 
The transfection results achieved suggest that the length of the spacer arm has a minimal effect 
on the siRNA transfection, in this study. This is evident when comparing the results achieved by 
MSO9 (with a 12 atom spacer) and Chol-T (6 atom spacer), where both the liposomes exhibited 
similar levels of transfection when the luciferase activity was measured.  
 
Maximum gene knockdown for the non-pegylated and pegylated MSO9 liposomes was evident 
at the optimum binding ratios for each liposome. This trend was not observed with the pegylated 
and non-pegylated Chol-T liposomes as optimum transfection for Chol-T was at the sub-
optimum binding ratio, for 2% PEG 2000 Chol-T was at the optimum binding ratio and for the 5% 
PEG 2000 Chol-T maximum gene knockdown occurred at the supra-optimum binding ratio. These 
results could be attributed to the differences in the sizes of the lipoplexes as well as the charge 
ratios which may have affected the transfection results (Higuchi et al., 2006; Torchillin et al., 
2003). Studies have shown that a relationship exists between the net charge of the lipoplexes and 
their effectiveness in transfection where, in most cases, a small net positive charge is required for 
in vitro transfection. Studies conducted have reported the use of charge ratios between 1:1 to 
1:10 (-/+). This resultant positive charge can enhance the interaction with cellular membranes 
which are known to have a net negative charge (Torchillin et al., 2003).  
 
The transfection results achieved with the siRNA complexed to the cationic liposomes showed 
higher levels of gene knockdown as compared to the corresponding concentration of the naked 
siRNA. This suggests that the complexation of the siRNA with the cationic liposomes is able to 
overcome cellular barriers as well as protect the siRNA from nuclease degradation and hence, a 
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greater amount of the siRNA became available to the cells which resulted in a significant gene 
knockdown.  
 
The use of negative controls is also important in RNAi studies. An accepted negative control for 
siRNA is the use of a control siRNA duplex with a scrambled sequence, which does not contain 
a perfect match in the genome (Shan et al., 2009). This negative control was applied in this 
study, in addition, the results were compared to luciferase activity in untreated cells. The 
transfection results achieved for the negative control are represented in Figures 4.7 (a-c) and 4.8 
(a-c). 
 
To ensure that knockdown of the luciferase gene was achieved due to the introduction of the 
anti-luciferase siRNA, the transfection experiment was repeated, however, the siGENOME non-
targeting siRNA was used as opposed to the anti-luciferase siRNA. The results obtained for this 
transfection assay showed that gene knockdown did not occur. The results for this assay show 
that the luciferase expression was very high and, in some instances, the cells treated with the 
siRNA lipoplexes exhibited higher levels of luciferase activity as compared to the control. Since 
non-targeting siRNA was used for this transfection study, the results obtained support those that 
were achieved for the luciferase assay where anti-luciferase siRNA was used and, therefore, it 
can be deduced that knockdown of the luciferase gene occurred as a result of the delivery of the 


























Figure 4.7 (c) 
 
Figure 4.7: Transfection studies of cationic liposome: non-targeting siRNA complexes in 
HeLa tat luc cells in vitro. siRNA concentrations utilized were 20 nM, 30 nM 
and 50 nM. 
  (a) Varying concentrations of Chol-T (0.4 g, 0.54 g, 0.67 g/10 l), (0.6 
g, 0.8 g, 1 g/10 l), (1.01 g, 1.34g, 1.68 g/10 l) for the 20 nM,    
30 nM and 50 nM concentrations, respectively, 
  (b) Varying concentrations of 2% PEG2000Chol –T (0.54 g, 0.67 g, 0.8 
g/10 l), (0.8 g, 1 g, 1.2 g/10 l), (1.34 g, 1.68 g, 2.02 g/10 l) 
for the 20 nM, 30 nM and 50 nM concentrations, respectively,  
  (c) Varying concentrations of 5% PEG2000Chol -T (0.8 g, 0.94 g, 1.07 
g/10l), (1.2 g, 1.4 g, 1.6 g/10 l), (2.02 g, 2.35 g, 2.69 g/10 l) 
for the 20 nM, 30 nM and 50 nM concentrations, respectively, 
   in a total volume of 0.25 ml medium (MEM). Control 1 contained HeLa tat luc 
cells only and Control 2 contained HeLa tat luc cells and siRNA only. Data 
presented as a means ± S.D (n= 3) (* p < 0.05). 
 


























Figure 4.8 (c) 
 
Figure 4.8: Transfection studies of cationic liposome: non-targeting siRNA complexes in 
HeLa tat luc cells in vitro. siRNA concentrations utilized were 20 nM, 30 nM 
and 50 nM.  
 (a) Varying concentrations of MSO9 (0.67 g, 0.8 g, 0.94 g/10 l), (1 g, 
1.2 g, 1.4g/10 l), (1.68 g, 2.02 g, 2.4 g/10 l) for the 20 nM,        
30 nM and 50 nM concentrations, respectively, 
 (b) Varying concentrations of 2% PEG2000 MSO9 (2.95 g, 3.08 g, 3.22 
g/10 l), (4.4 g, 4.6 g, 4.8g/10 l), (7.4 g, 7.7 g, 8.06 g/10 l) for 
the 20 nM, 30 nM and 50 nM concentrations, respectively, 
 (c) Varying concentrations of 5% PEG2000 MSO9 (2 g, 2.68 g, 3.35 g/10 
l), (3 g, 4 g, 5 g/10 l), (5.04 g, 6.72 g, 8.4 g/10 l) for the        
20 nM, 30 nM and 50 nM concentrations, respectively, 
  in a total volume of 0.25 ml medium (MEM). Control 1 contained HeLa tat luc  
 cells only and Control 2 contained HeLa tat luc cells and siRNA only. Data  









A trend that was evident was that as the degree of pegylation increased, there was a marginal but 
measurable decrease in the transfection efficiency of the cationic liposomes. This occurred with 
the liposomes prepared with both cytofectins, Chol-T and MSO9. This is consistent with the 
observations made by Vandenbrouke et al (2008), Zhang et al (2010) and Yang et al (2009). 
This negative effect of pegylation has been studied intensively for plasmid DNA delivery and it 
has been suggested by Desphande et al (2004) that the presence of PEG in lipoplexes results in 
reduced cellular binding and uptake. Yang et al proposed that this result may be attributed to the 
shielded positive charges of the liposome due to the incorporation of the PEG moiety and also 
the long PEG chain may produce a steric hindrance effect (Yang et al., 2009). It has also been 
said that the endosomal release of the nucleic acids into the cytoplasm may be inhibited by 
pegylation (Vandenbrouke et al., 2008). Song et al (2002) showed that pegylation of lipoplexes 
did not inhibit cellular uptake and, therefore, it is possible that this decrease in transfection 
efficiency is located at the endosomal escape step (Kim et al., 2010). 
 
It has been reported that serum impairs the transfection efficiency of cationic liposomes; 
therefore, serum free medium is often used for the first few hours. Studies have shown that this 
inhibition may arise due to the presence of negatively charged proteins in the serum. These 
proteins can become adsorbed onto the surface of the lipoplex which results in their aggregation 
and precipitation or the lipoplex may destabilize which results in pre-mature release of nucleic 
acids and, therefore, transfection may fail (Li et al., 2011). Once the serum free medium is 
removed, the lipoplex is not displaced from the cell surface, but remains tightly bound and is 
continuously internalized into the cell (Singh, 1998).   
 
The detection of luciferase gene knockdown in the HeLa tat luc cell line was determined using 
the luciferase assay. Luciferase is a 62 kD monomeric protein and post translational processing is 
not required for enzymatic activity, therefore, it has the ability to function as a reporter gene 
(Singh, 1998). The reaction involves the ATP-dependant oxidative decarboxylation of beetle 
luciferin which produces light at a wavelength of 562 nm (Roche Practical Manual). The reaction 




 i.  Luciferase + Luciferin + ATP               Luciferase.luciferyl-AMP + Ppi 
ii. Luciferase.luciferyl-AMP + O2             Luciferase + oxyluciferin + AMP + CO2 + Light 
 
The photon emmission deteriorates following the mixing of the enzyme and substrate. The light 
intensity is dependent on temperature, the optimum being room temperature (20-25 °C) 
therefore; all reagents are required to equilibrate to room temperature before proceeding with the 
assay. 
 
The results obtained for the liposomal formulations in this study warrant their further 
development for in vivo studies where a gene to be targeted can be expressed in rat models and, 
in doing so, the therapeutic potential of these formulations can be determined. 
 














The RNAi phenomenon refers to the process of post transcriptional gene silencing mediated by 
siRNA. Theoretically, the process of RNAi can be used for the knockdown of any mRNA 
expression and the therapeutic siRNA can be designed, provided that the sequence of the target 
gene is known. Hence, siRNA mediated RNAi has emerged not only as a useful biological tool 
for the determination of gene functions but also has therapeutic potential for the treatment of 
various human diseases (Guo et al., 2010). The numerous potential applications of these siRNAs 
have not yet been fully exploited due to the lack of a delivery vehicle that can be administered 
safely, efficiently and repeatedly (Sioud and Sørenson, 2003). Cationic liposomes represent 
delivery vehicles that can meet these requirements. Efficient gene delivery can be achieved with 
cationic liposomes under in vitro conditions, however, under in vivo conditions they have been 
shown to exhibit poor circulation time in the blood system, a problem which can be 
circumvented by the introduction of PEG. PEG is said to enhance the circulation time of the 
liposome in vivo, by preventing the binding of plasma proteins to the liposomal surface and, in 
doing so, RES uptake is reduced. 
 
Pegylated and non-pegylated cationic liposomes were prepared with either cytofectin Chol-T or 
MSO9. All liposomal formulations contained DOPE and varying amounts of DSPE-PEG2000 was 
introduced into the pegylated liposomal formulations. The liposomes were prepared using the 
thin film hydration- sonication technique. All the liposome preparations were characterized using 
cryo-TEM which revealed the unilamellar nature of the liposomes. siRNA binding to the cationic 
liposome was demonstrated using the band shift assay and these siRNA lipoplexes were 
characterized using cryo-TEM. The siRNA lipoplexes appeared to exist as spherical clusters, 
some of which also exhibited a deformable nature. The liposomes were also shown to offer 




The ratios of the siRNA: cationic liposome complexes utilized in transfection studies were 
determined from the binding studies. These complexes showed minimal toxicity to the HeLa tat 
luc cell line. Transfection studies were carried out using the luciferase assay and the anti-
luciferase siRNA was utilized for this study. It appears from the results that the length of the 
spacer arm did not affect the transfection efficiency as MSO9, which has a 12 atom spacer, 
exhibited similar levels of transfection when compared to Chol-T, whose spacer arm consists of 
6 atoms.  All the cationic liposome: siRNA complexes showed efficient knockdown of the 
luciferase gene with pegylated cationic liposomes showing marginally lower levels of gene 
knockdown as compared to their non-pegylated counterparts. The exact mechanism responsible 
for this reduction in transfection requires further investigation. However, the drawbacks 
associated with pegylated cationic liposomes can be overcome by the introduction of PEG-lipids 
such as PEG-ceramides which are capable of diffusing out of the liposome or PEG-lipids that are 
acid labile. Here, the PEG moieties of the liposome will become detached at a lower pH, much 
like the pH that exists in the endosomal vesicle. These types of modifications can result in the 
controlled removal of the PEG moiety and, therefore, the biological activity of the pegylated 
liposome can be improved (Buyens et al., 2009).  
 
To further enhance the efficiency of the cationic liposomes in this study, targeting ligands can be 
introduced into the liposomal formulation which will increase the specificity of the liposome to a 
particular tissue, for example, by introducing asialoglycoproteins to the liposomal formulation, 
hepatocytes can be specifically targeted. 
 
The findings in this study suggest that these liposomal formulations have the potential for 
clinical gene delivery and hence, should be further evaluated to determine their therapeutic 
potential under in vivo conditions. Furtermore, it has shown that RNAi is a useful tool for the 
downregulation of gene expression. One of the main objectives in the development of the non-
viral delivery system for siRNA delivery is the use of these systems for the treatment of diseases 
in the future and hence, the targeting of a specific gene linked to the disease. However, there are 
many concerns that need to be overcome before RNAi can be applied as a therapeutic modality 
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as there is great importance in understanding the mechanism fully before it can be effective in 
clinical applications. Nevertheless, due to the speed at which new discoveries are being made, it 
is anticipated that an ideal vector that is safe, effective and stable will be prepared allowing 
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